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Accelerated tumor cell repopulation during radiation therapy is one of the leading
causes for low survival rates of head-and-neck cancer patients. The therapeutic
effectiveness of radiotherapy could be improved by selectively targeting proliferating

tumor subvolumes with higher doses of radiation. Positron emission tomography (PET)
imaging with 3´-deoxy-3´-18F-fluorothymidine (FLT) has shown great potential as a noninvasive approach to characterizing the proliferation status of tumors. This thesis
focuses on histopathological validation of FLT PET imaging specifically for imageguidance applications in biologically adaptive radiotherapy. The lack of experimental
data supporting the use of FLT PET imaging for radiotherapy guidance is addressed by
developing a novel methodology for histopathological validation of PET imaging. Using
this new approach, the spatial concordance between the intratumoral pattern of FLT
uptake and the spatial distribution of cell proliferation is demonstrated in animal tumors.
First, a two-dimensional analysis is conducted comparing the microscopic FLT uptake
as imaged with autoradiography and the distribution of active cell proliferation markers
imaged with immunofluorescent microscopy. It was observed that when tumors present
a pattern of cell proliferation that is highly dispersed throughout the tumor, even highresolution imaging modalities such as autoradiography could not accurately determine
the extent and spatial distribution of proliferative tumor subvolumes. While microscopic
spatial coincidence between high FLT uptake regions and actively proliferative
subvolumes was demonstrated in tumors with highly compartmentalized/aggregated
features of cell proliferation, there were no conclusive results across the entire set of
utilized tumor specimens. This emphasized the need for addressing the limited
resolution of FLT PET when imaging microscopic patterns of cell proliferation. This
issue was emphasized in the second part of the thesis where the spatial concordance
between volumes segmented on FLT simulated FLT PET images and the three
dimensional spatial distribution of cell proliferation markers was analyzed.

1. Introduction
1.1 Biologically adaptive radiotherapy
According to the National Institute of Health, half of all cancer patients receive
some type of radiation therapy during the course of their treatment. Radiotherapy is
therefore standard care for many cancer patients. It uses different methods of delivering
ionizing radiation to reduce the size or eradicate tumors. This is done by radiation
induced tumor cell death, a complex biochemical process initialized by DNA damage
produced during cell irradiation. However, all living cells are susceptible to radiation
induced cell death. Therefore, the universal goal in radiotherapy is to maximize tumor
cell kill while limiting the normal tissue irradiation and potential treatment-induced
secondary effects. This can be partially achieved by utilizing complex spatial
arrangements of radiation beams/sources that create optimal deliverable dose
distributions, which focus the majority of the radiation dose in the tumor while sparing
the normal tissue. However, the concept of “optimal” dose distributions is a paradigm
that is continually evolving.
Solid tumors are characterized by highly complex microenvironments (Figure 1),
which create spatially heterogeneous populations of tumor cells with varying sensitivity
to ionizing radiation1. It has been observed that most disease recurrences in locally
advanced cancers occur in regions of the tumor that are either poorly vascularized
(hypoxic)2, 3, or have a large fraction of actively proliferating cells4-6. Therefore, the
radiation dose could be modulated such that the resulting optimal deliverable dose
distribution would account for the spatially variable levels of radiosensitivity found within
1

a defined target7, 8. Computer simulation studies indicate that radiation treatments that
are selectively targeting ‘high-risk’ tumor subvolumes with increased doses of radiation
could potentially have better outcomes than treatments that deliver uniform doses to the
entire tumor9-12.

Figure 1. Overlaid immunofluorescence microscopy images from thin adjacent tissue sections (FaDu tumor
xenograft), presenting different functional aspects of tumor microenvironment surrounding a necrotic core.

For selective dose escalation treatments to be efficacious, different tumor regions
need to be accurately characterized in terms of aggressiveness and/or risk of
recurrence based on local biological features, prior to the initiation of treatment.
However, the majority of radiation treatments are currently planned based on x-ray
computed tomography (CT) imaging studies (Figure 2A). Due to the physics of image
acquisition, CT images cannot provide a detailed spatial description of the tumor
content or heterogeneity, hence no pertinent information about the biological status of
2

different tumor subvolumes is used to plan radiation treatments. The current status quo
in CT-based treatment planning is that tumors can be regarded as masses of identical
cells uniformly distributed within a physician-defined target volume. Under this
assumption, it was shown that the tumor control probability is correlated with the
minimum dose delivered to the whole tumor13, and that the maximum therapeutic ratio
of a treatment can be achieved by maximizing the degree of uniformity in the dose
distribution covering the target volume14, 15. After decades of clinical utilization, the
uniform dose “optimal” distribution has become a powerful dogma in radiation oncology
since it simplifies dose prescription and reporting, creating a robust approach to
computing tumor control probabilities, and streamlining the accumulation of clinical
data16. As a result, treatment planning with intentionally non-uniform dose distributions
is not a common practice in conventional external beam radiotherapy, even if it may
present better curative strategies10, 12.
Until recently, clinical in vivo exploration of tumor biology has been limited to
invasive techniques (e.g. image-guided biopsy). However, the developing field of
molecular imaging enables non-invasive visualization of different functional or
pathological aspects of tumor biology. Biomarker probes can be administered via
systemic circulation. Their specific binding to tumor cells enables the visualization of
tumor biology with high contrast using functional imaging modalities such as positron
emission tomography (PET) among others (Figure 2B). This highly sensitive and
quantitative imaging modality can provide the information necessary in establishing a
direct correlation between pretreatment imaging parameters, the delivered dose
distribution and treatment outcome17. Once specific tumor regions can be identified as
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being at-risk of recurrence based on individual patient PET imaging data18, the
treatment can be customized, the clinical decision consisting in properly assigning dose
to these tumor subvolumes for treatment delivery (Figure 2C). Currently, this remains a
subjective issue, with physicians prescribing an empirical dose boost to high-risk tumor
regions, based on clinical experience and/or patient population data9, 19-21.

Figure 2. A. Planning CT with CT-delineated gross tumor volume. B. Fusion of planning CT and corresponding
18
F-FDG PET image with PET-delineated gross tumor volume. C. Planning contours of target volumes: pink –
50.3 Gy; blue – 68 Gy; light blue – 72 Gy. D. Overlaid calculated heterogeneous dose distribution targeting the
21
PET-delineated gross tumor volume with higher doses. Figure replicated from Troost et al.

The concept of biologically adaptive radiotherapy as understood in this work
refers to external beam radiotherapy strategies where the delivered treatment is
4

customized based on individual patient biology, including but not limited to tailoring an
optimal dose distribution that accounts for radioresistant tumor subvolumes identified by
functional imaging (specifically PET imaging). While many of the validation steps
involved in the clinical implementation of biologically adaptive radiotherapy are yet to be
taken, many clinical trials have been developed in order to make this type of
individualized therapy available to cancer patients20, 22. As research in this particular
aspect of radiotherapy is very active, one concept remains unchanged. In biologically
adaptive radiotherapy using PET imaging, the spatial pattern of the tracer uptake
observed in PET images will be utilized to derive inhomogeneous dose distributions
delivering higher doses to regions with high tracer uptake. This strategy is based on the
hypothesis that planning PET images are accurate spatial representations of the
underlying targeted biology.

In biologically adaptive radiotherapy using PET imaging, the spatial pattern
of tracer uptake recorded in PET images will be utilized to derive
inhomogeneous dose distributions delivering higher doses to regions with
high tracer uptake.

1.2 Head and neck cancer: biology and radiation therapy
Head and neck cancer patients include those who have tumor growths in the
nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. Most head and neck
cancer patients are diagnosed in advanced stages23. Because of that, aggressive
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treatments including radiation therapy fail to improve the 20-50% five-year survival
rate24, 25. In a multicenter randomized trial comparing radiotherapy with concomitant
radio-chemotherapy for advanced-stage oropharynx carcinoma, Denis et al. have
observed that only 16% of patients receiving radiotherapy alone survived 5 years or
more, added chemotherapy slightly improving survival (22%)25. The introduction and
technological advancement of intensity-modulated radiotherapy (IMRT) have
significantly improved treatment conformity for head and neck patients, increasing
normal tissue sparing and concomitantly raising the patient quality of life posttreatment26. In the cited study, the patients in the IMRT arm presented with better
salivary function of the parotid glands. Only 44% of the patients were diagnosed with
grade 2 or worse xerostomia when compared with 76% of the patients that received
conventional radiotherapy26. However, to date, IMRT has not improved survival of
advanced head and neck cancer patients. A need for dose escalation was emphasized
by the fact that most treatment failures are local, occurring within the treated volume.
For example in a study by Studer et al. 45 out of 46 patients (16% of patient population)
that presented with local failures at two years the recurrence was inside the treatment
field27.
Accelerated repopulation of tumor cells during radiotherapy is defined either
based on direct measurement of doubling time of clonogenic cells obtained from biopsy
specimens or indirectly by recording the extra dose necessary to control 50% of tumors
when prolonged treatments are utilized. Many classic studies have established that the
rate of cell proliferation in untreated solid tumors decreases with increasing distance
from sources of nutrients and oxygen. As cells proximal to vessels are killed by
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radiotherapy, the levels of nutrients and oxygen available of remaining cells are
significantly improved. This activates cell proliferation in previously quiescent cancerous
cells, increasing the fraction of cells that are repopulating the tumor mass. Furthermore,
it has been proposed that tumor cells that are differentiating during radiotherapy have a
higher probability of retaining clonogenic status than cells that differentiate in normal
conditions, and their rate of proliferation may be faster with fewer aborted cell divisions.
Furthermore, the radiation cellular damage has been shown to activate proliferation
mechanisms in human squamous cell carcinoma134. The treatment failures in head and
neck cancers seem to be associated with accelerated repopulation of tumor cells during
radiotherapy5, 28-30. Uniform dose escalation trials have shown promising results
regarding tumor control, but also an increase of severe toxicities associated with
irradiation of organs in close proximity of the head and neck tumors (oral mucosa,
parotid glands, etc.)31, 32. Furthermore, the incidence of treatment-associated toxicity
greatly depends on the volume of irradiated normal tissue26, 33. In terms of biologically
adaptive radiotherapy, the effectiveness of the treatments can be increased at the same
time while limiting toxicities associated with escalating the radiation doses to the entire
tumor volume30, 34-38, by delivering escalated doses only to higher-risk tumor subvolumes
characterized by active cell proliferation. No dose-escalation trials have been conducted
utilizing FLT PET to guide the delivered dose distributions. However, FDG-based trials
have shown the feasibility of such an approach20.
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By delivering inhomogeneous dose distributions targeting actively
proliferating tumor subvolumes with increased doses, the therapeutic ratio
of IMRT for head-and-neck patients could be significantly increased.

1.3 Fluorothymidine – imaging cell proliferation in head and neck cancer
Multiple non-invasive imaging methods have been proposed for in vivo imaging
of cell proliferation including magnetic resonance imaging (MRI) spectroscopy39, and
PET utilizing tracers that are incorporated into DNA: [11C-methyl] thymidine, 1-(2’Deoxy-2’-[18F]-fluoro-1-β-D-arabinofuranosyl)-thymine, 1-(2’-Deoxy-2’-[18F]-fluoro-1-β-Darabinofuranosyl-uracyl)-bromouracil, and tracers that are indirectly related to cell
proliferation. One of these latter, 3´-Deoxy-3´-[18F]-fluorothymidine (FLT). PET with 18F
labeled FLT has proved to be the most promising imaging modality for identifying
proliferative areas of the tumors40.
FLT is currently produced only for research purposes and is under investigation
for clinical implementation as a PET tracer for cell proliferation41. FLT is a synthetic
thymidine analog (Figure 3). Extensive validation efforts have been devoted to
determining the biological mechanism of FLT specific uptake in proliferating cells.
Currently it is assumed that FLT uptake in solid tumors is determined by the enzymatic
activity of thymidine kinase 1 (TK1), a cytosolic enzyme, with high phosphorylating
activity during the DNA synthetic phase of the cell cycle42.
Once incorporated in the cell, FLT can serve as substrate for TK1. Thymidine
phosphorylation is the first step in the thymidine salvage pathway for DNA synthesis.
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While thymidine phosphates are incorporated in DNA, FLT phosphates are not due to a
missing hydroxyl group in their structure (Figure 3). Therefore, FLT phosphates remain
trapped intracellularly43, providing specific high uptake in cells where TK1 is
upregulated44, 45, such as actively proliferating tumor cells.

18

Figure 3. 3′-Deoxy-3′- F-fluorothymidine chemical structure. The only difference from the pyrimidinic nucleotide
18
is the F isotope replacing a hydroxyl group at the 3´ position on the ribose ring.

However, recent studies involving correlation of in vivo FLT uptake values (static
and dynamic PET imaging) and TK1 expression/activity assays in patients, provided no
direct evidence of the stated hypothesis about TK1 phosphorylation being the ratelimiting step in FLT accumulation46, 47. New evidence suggests that the FLT uptake
mechanism is a complex interplay between membrane nucleoside transporters
expression and activity48-50, competitive binding of nucleoside transporters between FLT
and endogenous thymidine51-53, and relative metabolic equilibrium between FLT
influx/efflux and activity of TK1 and enzymes that dephosphorylate FLT43, 54.
Nevertheless, ex vivo assays of cell proliferation obtained from surgical resection tumor
specimens (e.g. Ki-67 labeling index) correlate with in vivo tumor uptake of FLT in a
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wide variety of human tumors, empirically confirming FLT as a tracer of cell
proliferation46, 47, 55, 56.

Currently under investigation, FLT is a promising tracer for non-invasive
imaging of cancer cell proliferation and could be used to identify the
location and extent of tumor subvolumes that are actively proliferating.

1.4 Current status of validation efforts
Validation of any biomarker assay requires demonstration that the performance
of the assay is suitable and reliable for the intended analytical application57. As
mentioned in section 1.1, in biologically adaptive radiotherapy, the spatial pattern of
tracer uptake identified on PET determines the inhomogeneous dose distribution giving
higher doses to tumor regions with high risk of recurrence of disease. Therefore, by
demonstrating the spatial concordance between the pattern of FLT uptake and the
intratumoral distribution of cell proliferation, FLT PET images can be safely and
effectively used to identify and delineate tumor subvolumes characterized by active cell
proliferation to be used in biologically adaptive radiotherapy. Validating spatial
concordance between the FLT uptake pattern and the distribution of actively
proliferating cells is equivalent to demonstrating that the tumor regions that contain
tumor cells that are actively proliferating are the same tumor regions which present
higher tracer uptake on FLT PET images (or autoradiography images).
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Currently, FLT PET imaging is being proposed for utilization mainly for diagnostic
purposes38. Specifically, its suggested uses include indication of early treatment
response35, 56, 58, 59, and prediction of long-term treatment response to radiotherapy60, 61. In
these diagnostic applications of PET imaging in oncology, PET data is used to extract
metrics such as average, and/or maximum standard uptake values (SUV), that allow to
test for the presence of the disease or to predict certain characteristics of the tumor as a
whole. Validation of such PET imaging applications is currently conducted by
establishing correlations between single-value SUV-based metrics characterizing in vivo
PET tracer uptake and ex vivo pathological indices representative of the target biology
(e.g. proliferation index) over a population of patients46, 54, 55, 62-64. Since these studies
utilize single-value metrics, no spatial information about the pattern of FLT uptake is
retained in the analysis. Therefore, the spatial co-localization between the
heterogeneous PET tracer uptake and that of biological markers of cell proliferation is
not demonstrated. Up to date, there are no published data verifying the spatial
concordance between intratumoral distribution of FLT uptake and the pattern of tumor
cell proliferation.

There is no validation data demonstrating the spatial coincidence between
areas of high uptake FLT in PET images and regions of intratumoral active
cell proliferation.
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1.5 Study goal
FLT was described as a novel PET tracer specifically designed to non-invasively
image active cell proliferation. Its specific high uptake in proliferating cells has been
demonstrated in vitro, but up to date there is no study validating that areas of high in
vivo FLT uptake are spatially co-localized with areas of active proliferation in individual
tumor specimens. In proposed scenarios where FLT PET would be used in biologically
adaptive radiotherapy for image-guidance, validation of spatial concordance with cell
proliferation is necessary. Many factors can affect the in vivo intratumoral uptake of
FLT. For example, the irregularities of tumor vascular system and its structural
deficiencies65-67 can potentially modulate the levels of FLT uptake by limiting the regional
supply of the tracer to individual cells. Furthermore, by analyzing PET imaging from first
principles, it is well known that there are inherent limitations to the size of the smallest
object that this imaging modality can accurately resolve68-71. Tumor microenvironment
presents a spatially heterogeneous distribution of viable and necrotic tissue, welloxygenated and hypoxic regions, proliferative and non-proliferative subvolumes. The
variation of these biological spatial characteristics spans distances that are usually
smaller than current inherent resolution of clinical PET scanners (Figure 4). When using
PET imaging to guide the delivery of radiotherapy, inherent averaging effects can
significantly alter the resulting images, making it necessary to demonstrate the spatial
coincidence between the pattern of tracer uptake as seen in PET images and the
pattern of the underlying biological parameter of interest. Specifically, this type of
analysis of can provide important information about the clinical situations where PET
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imaging provide enough spatial information about the underlying targeted biology, and
how can this information may be safely and efficaciously used for treatment planning for
head and neck patients.
The research work presented herein is an attempt to address a major gap in the
data supporting FLT PET imaging for the specific task of radiation therapy target volume
definition, by establishing a methodology for in vivo validation of FLT PET for
indentifying the extent and spatial distribution of cancer cell proliferation. This proposed
study will also provide the first available sets of experimental data demonstrating the
spatial co-localization of the intratumoral distribution of FLT uptake and cell proliferation
markers.

Figure 4. Immunofluorescence microscopy image of tumor microenvironment. Squares are representative of
different PET resolution: submillimiter resolution (750 µm) for small aperture preclinical systems; 1.5 mm
resolution of current preclinical system Siemens Inveon; 4.1 mm resolution of current time-of-flight clinical system
Siemens Biograph mCT.
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1.7 Research questions
The registration of in vivo PET images with histological samples has been shown
to necessitate a technically complex methodology72, 73, that still does not always provide
the accuracy needed for analysis between in vivo PET images and ex vivo pathological
images69, 74, 75. An alternative way to evaluate the concordance between the PET tracer
intratumoral distribution and that of its intended target is to use thin tissue sections
obtained from a surgically excised whole tumor specimen from a patient or an animal
injected with the tracer before the surgery.

Figure 5. Comparison between spatial pattern of intratumoral uptake of FLT (DAR image, left) and spatial
distribution of cell proliferation markers (uptake of bromodeoxyuridine on IFM image, right). Images were obtained
from adjacent tissue sections.

Using these tissue sections, it is possible to visualize the two-dimensional
microscopic distribution of the PET tracer distribution using digital autoradiography
(DAR) and the spatial distribution of relevant biological markers using immunofluorescent microscopy (IFM). These high-resolution imaging modalities are described
in detail in Chapter 2. By co-registering these data and performing statistical analysis, it
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is possible to evaluate how well the PET tracer distribution depicts the spatial pattern of
the tracer’s intended biological target (Figure 5).
This direct spatial comparison was utilized throughout this thesis with two specific
goals. First, to demonstrate that at a microscopic level, there is spatial concordance
between the intratumoral FLT pattern of uptake and the spatial distribution of cell
proliferation markers. Confirming this spatial coincidence is an important clinical goal of
the study, since it provides direct evidence that the tracer specifically targets actively
proliferating cells in vivo.

Specific Aim #1
Analyze the spatial concordance between the intratumoral pattern of FLT
uptake and the spatial distribution of cell proliferation markers at a
microscopic level

In order to realize the potential of FLT PET for image-guidance in biologically
adaptive radiotherapy, it is necessary to analyze the spatial coincidence between the
regions of interest contoured from macroscopic FLT PET images and underlying tumor
subvolumes, segmented from microscopic cell proliferation images. Therefore, the
second aim of this thesis involved developing and demonstrating utilization for a set of
validation tools that will eventually enable comparing FLT PET synthetic images
obtained from stacked DAR images, to the three-dimensional spatial distribution of cell
proliferation markers. This was done as to observe the effects that the limited resolution
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of PET induces on the FLT images’ ability to determine the spatial extent and spatial
distribution of proliferative tumor subvolumes.

Specific Aim #2
Develop histopathologic validation tools for spatial concordance analysis
between volumes segmented on FLT simulated PET images and the three
dimensional spatial distribution of cell proliferation markers

1.8 Summary of thesis
Specific aim #1 is covered in chapters 2 and 3. Chapter 2 describes the basic
experimental methods utilized throughout the study involving tumor models, tissue
processing, tumor microenvironment imaging and image processing techniques. More
important, this chapter introduces a co-registration workflow that was developed for
aligning DAR and IFM images throughout the projects presented in this thesis. The
utilized image registration tools and an evaluation of the registration error were
presented in detail. In chapter 3, a novel spatial concordance analysis methodology is
introduced. Spatial concordance between intratumoral FLT uptake pattern and cell
proliferation at a microscopic level are presented and discussed.
Specific aim #2 is covered in chapters 4 and 5. A method to create synthetic PET
images from DAR images is presented in chapter 4. Chapter 5 presents a methodology
for spatial concordance analysis between simulated FLT PET images and images of
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tumor cell proliferation. A limited set of results are presented for head-and-neck tumor
xenograft synthetic PET images as an illustration of the method.
The conclusions of the thesis are presented in chapter 6.
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2. Comprehensive approach to co-registration of autoradiography and
microscopy images acquired from a set of sequential tissue sections
2.1 Introduction
Using thin tissue sections from tumor specimens that were injected with various
tracers, it is possible to visualize the two-dimensional microscopic distribution of the
PET tracer distribution using digital autoradiography (DAR) and the spatial distribution
of relevant biological markers using immuno-fluorescent microscopy (IFM). Comparison
between these imaging sets is an often-utilized validation method showing that the
investigated PET tracer specifically binds a targeted biological molecule/pathway.
Autoradiography is a two-dimensional imaging modality that records the pattern
of interactions of charged particles (or photons) emitted during decay of a distribution of
radioactive sources. In the case of DAR, phosphor plates are the detection and
recording medium. DAR images of the distribution of radiotracer within a thin tissue
sample (Figure 5), is an example of “in vivo autoradiography” because the tracer was
administered and allowed to diffuse and bind while the animal was still alive. DAR is a
highly sensitive imaging modality, with a wide dynamic range (5 orders of magnitude),
and presents a linear response to the activity concentration present in a sample.
Furthermore, the tissue sample is in close proximity with the imaging plate (<20 µm).
This is of particular importance since this study uses β-particle autoradiography.
Energetic β decay particles present non-negligible ranges before interaction with the
detectors. By minimizing the tissue section thickness and the distance between tissue
and detecting media, the DAR setup ensures that the image captured by the imaging
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plate is a high-resolution representation of the radiotracer uptake distribution in that
particular tissue section.
Immuno-fluorescence microscopy is a light microscopy technique that utilizes a
fluorescent microscope to visualize the distribution of specific target molecules within a
biological sample (Figure 5). Specific fluorescent antibodies are used to the tumorspecific molecules/biological pathways that are investigated. By stimulating the
fluorescent tags of the bound antibodies, a fluorescent signal is obtained and recorded
by high-resolution digital cameras. The spatial distribution of the recorded specific
markers is representative of the distribution of the targeted molecule or pathway in that
particular tissue section. In this study, IFM images are utilized to obtain the spatial
distribution of specified cell proliferation markers, among other functional aspects of the
tumor microenvironment.
As mentioned in the previous chapter, the first specific aim of the thesis is to
evaluate the spatial concordance between the FLT PET tracer intratumoral distribution
and the spatial distribution of cell proliferation markers at a microscopic level. Before
any statistical analysis is conducted, it is important to minimize the geometrical
misalignments between the two images obtained from different modalities, which can
introduce unaccounted confounding effects.
To ensure the most accurate analysis results, all images (acquired through DAR
and IFM techniques) should be acquired from a single tissue section. Most often, this is
not feasible due to different technical aspects of the image acquisition process.
Consequently, several studies investigating the co-localization of a PET tracer with its
biological target used a set of sequential tissue sections to perform DAR and
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immunohistochemical staining/imaging to reveal multiple aspects of the tumor biology76. Therefore, beyond the difficulties of registering data from different imaging

78

modalities, such data acquisition methods pose the additional challenge of coregistration of all the images acquired from different, albeit adjacent tissue sections.
Even though the tissue sections used are thin enough (several microns) to insure
minimum variation of the microenvironmental parameters of interest between adjacent
sections, tissue cutting, mounting on glass slides and chemical processing can
introduce non-linear deformations that prevent precise co-registration of the images
acquired from adjacent tissue sections by only using rigid affine transformations (those
allowing only translation, rotation, and scaling) . When DAR images are part of the
image dataset, objective co-registration of the images becomes even more difficult, as
the information content in DAR images is drastically different from microscopy images.
For this reason, the standard of manual affine co-registration of DAR with IFM images
tends to be highly subjective, when based on the tissue outline.
The purpose of the study presented here is to develop and evaluate a
methodology for objective co-registration of histopathological and DAR images acquired
from a set of sequential thin tumor tissue sections. The details of this study have been
previously published in the Journal of Nuclear Medicine79.

2.2 Experimental methods
Animals and tumor models
Human cancer cells were used to establish tumor xenografts in male athymic
mice (NCr-nu/nu, National Cancer Institute), by bilateral flank subcutaneous inoculation
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of 5×105 cells/site. This technique of heterotransplantation of human cancer cells into
immunodeficient rodents is a widely accepted protocol for development of preclinical
tumor models representative of the molecular characteristics of given human cancers.
Head and neck squamous cancer cells were used: a human hypopharyngeal cancer
line (FaDu) was utilized for four animals, and a laryngeal cancer line with an activating
mutation for EGFR (SQ-20B) was utilized for another four animals. Tumor growth was
assessed by caliper measurements and recorded every other day. Animal maintenance
and all experimental procedures were carried out according to the protocol approved by
the local Institutional Animal Care and Use Committee at Virginia Commonwealth
University.

Radiotracers
For this study, autoradiography was utilized to reveal the intratumoral distribution
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F-FLT PET tracer. 18F-FLT was produced by the Center of Molecular Imaging, Virginia

Commonwealth University (Richmond, VA). The synthesis followed an established
protocol, utilizing 5´-benzoyl-2,3´-anhydrothymidine as a precursor80, 81. 14C-FDG
(American Radiolabeled Chemicals, Inc.) was also injected to evaluate the difference in
the intratumoral distribution between FLT and FDG for a different study.

Tumor tissue collection
When the tumors reached 10-15 mm in diameter, the animals were anesthetized
by inhalation of a mixture of oxygen and Isofluorane. At 80 minutes before planned
animal euthanasia a bolus injection containing pimonidazole hydrochloride
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(Hypoxyprobe, HPI, Inc., Burlington, MA) 2.5 mg/20 g mouse, Hoechst 33342 (SigmaAldrich, St. Louis, MO) 0.4 mg/20 g mouse, 37 MBq 18F-FLT, and 185 kBq of 14C-FDG,
was administered by tail-vein injection, followed by two consecutive intraperitoneal
injections of bromodeoxyuridine (Sigma-Aldrich) 15 mg/20g mouse, at 50 and at 30
minutes before the animal sacrifice. After animal sacrifice, tumors were immediately
excised, embedded in Tissue-Tek OCT (Sakura Finetek), and frozen on dry ice. The
tumor specimens were sectioned with a Leica CM1850 UV cryostat (Leica
Microsystems) at 8 µm thickness. From each tumor, three stacks of at least 15
consecutive sections were obtained from the top, the middle, and the bottom of the
tumor specimen (≥45 sections per tumor). Each section was affixed onto a glass slide
for staining and visualization.

Autoradiography
One section (referred to as reference section below) was selected from each
stack of consecutive sections and used for phosphor plate autoradiography. On these
reference sections, registration marker dots were manually placed on the glass slide
around the tissue section, utilizing a mixture of 1 µl 14C ink (Moravek Biochemicals),
50 µg Hoechst, and all-purpose glue. The slides selected for DAR imaging were
covered with a layer of saran wrap to avoid contamination of the imaging plates with
long-lived radionuclide and exposed to phosphor plate for 4 hr. All exposures were
conducted at room temperature. 14C standards (American Radiolabeled Chemicals,
Inc.) were simultaneously exposed with the tissue sections. The imaging plate was read
with Fujifilm BAS-5000 Bio-Imaging Analyzer to obtain the image of 18F-FLT distribution.
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After the first exposure, 18F activity was allowed to decay for 1 day. Thereafter, a 4-day
exposure was initiated, as to obtain the image of distribution for the 14C-FDG tracer. In
the last step, another 4 hr exposure was performed to confirm the insignificant
contribution of 14C-FDG activity to the 18F-FLT image. The resulting images were
exported in TIFF format, at 25 µm/pixel resolution and 16-bit depth. The DAR images of
individual tumor sections (Figure 6 A-B) were cropped from a large image of the whole
phosphor plate containing multiple sections. The typical size of individual tissue section
image was on average 500 by 600 pixels, at 25 µm/pixel. The DAR images were
digitized and image intensity values were converted to actual activity (Bq/mm2). Prior to
registration, these individual tumor section DAR images were up-sampled to 2.5
µm/pixel using nearest-neighbor interpolation, preserving the original intensity values.
For 18F DAR, a scaling factor was experimentally derived to calibrate the image of the 4hour exposure to activity concentration (Bq/mm2), based on the 14C standards.

Tumor microenvironment imaging
In order to visualize different aspects of the tumor biology, such as cell
proliferation, hypoxia, blood flow patterns, a combination of previously described
immunohistochemical techniques were used77, 82-84. All types of acquired IFM images are
presented in Figure 6. For imaging of cell proliferation, two different staining techniques
were used, tracking proliferation from different perspectives. First, the distribution of
bromodeoxyuridine (BrdU) was investigated. The intratumoral uptake of BrdU, revealed
the density of dividing cells (in DNA synthetic phase of mitotic cycle) in the investigated
tissue sample. Since BrdU was injected before animal sacrifice, it was distributed via
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systemic circulation to the tumor tissue, and was made available to the cells through the
same pathways as the radiotracers. Therefore, BrdU was considered an exogenous
marker of cell proliferation. The second marker of cell proliferation was the endogenous
Ki-67 protein, upregulated in proliferating cells85. As Ki-67 is absent in quiescent cells
(G0 phase), it can provide an estimate of the density of actively cycling cells86.
Furthermore, the correlation between anti-BrdU and anti-Ki-67 labeling indices was
found to be statistically significant87.
Pimonidazole hydrochloride was used as a marker of hypoxia. Hoechst 33342
(Sigma-Aldrich) was utilized to track the tumor blood flow and diffusion, as this
fluorescent dye is transported through the tumor’s vasculature and preferentially binds
to nuclear regions rich in A-T base pairs in its diffusion path. DAPI (Sigma-Aldrich) is a
DNA specific fluorescent probe, specifically binding to nuclear regions rich in A-T base
pairs. This stain is applied after slide preparation, and it is aimed at revealing all nuclear
material present in the investigated tissue sample. Therefore, the resulting staining
distribution is indicative of the extent of the viable tissue on the respective tumor
section. Furthermore, the distribution of viable tissue vs. necrosis is verified by
obtaining Meyer’s hematoxylin and eosin (H&E) stain on an adjacent section. The
microenvironmental map is completed by the distribution of the vasculature. For this
purpose, the CD31 endothelial marker was utilized, a surface protein found on
endothelial cells of blood vessels, also known as platelet endothelial adhesion molecule
or PECAM-1. The immunofluorescent histochemical processing of the tissue sections
was automated utilizing the Ventana Discovery XT system (Ventana Medical Systems,
Inc., Tucson, AZ). H&E staining was performed manually.
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Figure 6. Complete coregistered image dataset for one stack of sequential tissue sections of a FaDu xenograft tumor.

Because of the long exposure times necessary for autoradiography and because
of the contact with the plastic film that can damage the tissue upon removal, the tissue
sections used for DAR were deemed unsuitable for any further immunohistochemical
processing. Therefore, the strategy depicted in Figure 7 was adopted: obtain DAR from
the reference section and microenvironment information from adjacent sections. All
25

microscopy images were acquired at 20X magnification using a motorized research
Olympus BX61 microscope, connected to X-Cite 120PC fluorescence illumination
system for IFM imaging, and an Applied Imaging SL50 automatic microscope slide
loader. The automated tiled image acquisition and reconstruction process was
controlled through the Ariol software (Genetix, San Jose, CA). All images were acquired
at 8-bit depth and had a 2.5 µm pixel size. The typical physical size of the image was on
average 5000 by 6000 pixels, varying with the extent of the tumor tissue.

Figure 7. Image acquisition and registration scheme. Green double arrows represent rigid point-set registration used
for the autoradiography and Hoechst images from the reference section. Blue dashed arrows represent manual rigid
registration of microscopy images from non-reference sections. Red solid arrows correspond to Hoechst-based
deformable registration.

2.3 Image registration methods and validation
A two-step registration approach was used as depicted in Figure 7. For each
individual tissue section used for data acquisition, all images obtained from this section
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were initially rigidly co-registered. Thereafter, these independent sets of rigidly
registered images representing individual tissue sections were registered together using
deformable registration.

Rigid Image Registration – Images Acquired from the Same Section
For the microscopy images obtained from the same tumor section, the
adjustments needed for registration were minor, as all tissue deformations induced
during section cutting and mounting would affect all of these images in the same way.
Misalignments could only be induced by the automated slide placement on the
microscope tray and, potentially, tissue shrinkage during subsequent
immunohistochemical processing.
To correct for these misalignments, manual rigid registration of these images was
performed in Photoshop CS4 Extended (Adobe), based on aligning tissue boundaries
(always visible due to the tissue auto-fluorescence or non-specific binding). Automated
image content-based registration was avoided since the microscopy images obtained
from the same tissue section represented radically different characteristics and features.
Registration of DAR with IFM images poses a different problem, as the former
are characterized by lower resolution and lack microscopic landmarks useful for coregistration and verification. Therefore, for the autoradiography and the Hoechst image
acquired from the reference tissue section a different registration method was used.
Instead of relying on the tissue outlines, a set of regular landmarks was created by
placing 8-12 dots of 14C ink mixed with Hoechst dye, around the tissue section on the
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glass slide. These dots (with the typical diameter of ~0.2 - 0.5 mm) were visible on both
autoradiography and Hoechst images (Figure 6 A-C).
For each marker dot, a weighted center of mass was obtained for the
autoradiography and microscopy images. Using at least six marker dots (selected
interactively), the rigid transformation needed to align the centers of mass of these dots
in the Hoechst image with those in the autoradiogram was obtained. The rigid transform
of the point coordinates was calculated using a MATLAB R2010a (MathWorks)
implementation of coherent point drift (CPD) algorithm88. The algorithm is available for
free download for research use at:
https://sites.google.com/site/myronenko/research/cpd. The resulting transformed image
intensity values were calculated using linear interpolation.
The coherent point drift algorithm is a probabilistic point set registration
algorithm, where the alignment of two distinct point sets is solved as a probability
density estimation problem. Specifically, the primary (stationary) point set is one of the
data sets, while the other point set (moving) is represented as the locations of the
centroids of a Gaussian mixture model. A mixture model is a probabilistic model utilized
to characterize the existence of sub-populations within an overall population, without
requiring a apriori identification of the sub-population to which an individual observation
belongs89. A Gaussian mixture model is a parametric mixture model represented as a
weighted sum of Gaussian component probability densities. The Gaussian mixture
model of the moving point set is fit to the primary data in an iterative fashion by
maximizing the likelihood (expectation-maximization algorithm). The specific
characteristic of this algorithm is that, for every iteration, the Gaussian mixture model
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centroids are forced to move coherently as a group, which preserves the topological
structure of the moving data set. The coherent point drift algorithm is accurate and
robust in case of missing data, initialization, and presence of noise. No specific
correspondences need to be defined between the point data sets88.

Deformable Image Registration – Images Acquired From Multiple Sections
As previously reported in histopathological image registration studies90, 91, tissue
cutting and slide preparation induce in each collected tissue section characteristic nonlinear deformations (tissue stretching, warping, etc.). Thus, deformable image
registration is needed to correctly align the images obtained from adjacent or spatially
proximate tissue sections.
As represented schematically in Figure 7, Hoechst IFM images were obtained
from all tumor sections. The typical diffusion distance of Hoechst in tissue is
approximately 100-250 µm84, significantly larger than the tissue section thickness (8
µm). Therefore, it was assumed that the majority of the Hoechst image features
observed in a set of consecutive tumor tissue sections are spatially constant, as
illustrated in Figure 8.

Figure 8. Fragments of Hoechst images acquired from five consecutive sections showing corresponding landmark
indicated with the white cross.
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Correspondingly, this spatial correspondence of Hoechst staining features can be used
to establish the deformations needed to register Hoechst images acquired from nonreference sections to the Hoechst image of the reference section.
To perform deformable registration of Hoechst images acquired from sequential
tissue sections, the open source Java-based Fiji plugin bundle (implemented in the NIH
ImageJ platform) was utilized. The Hoechst images were first rigidly registered
employing the Register Virtual Stack Slices plugin. For the reference Hoechst image
(acquired from the section used for autoradiography acquisition) and each of the nonreference Hoechst images (representing adjacent tissue sections), a set of
corresponding invariant features distributed through the area of the section was
identified using the Feature Extraction plugin employing a multi-scale oriented patch
feature extraction algorithm92. Using these features as soft registration landmarks, a
deformable image registration plugin, UnwarpJ, was employed93. This elastic
registration algorithm was specifically designed to handle the alignment of biological
images. The deformation field was expressed as a B-spline model. The registered
image smoothness was ensured by way of vector-spline regularization. The registration
field was estimated each time through the minimization of a three parameter objective
function containing a data term (the mean squared error between images), the error in
mapping corresponding landmarks (soft constrain), and a regularization term.
The derived deformable transformation was then applied to the Hoechst image
for which it was calculated, and to all other images obtained from that particular tumor
section. By repeating this procedure for the rest of non-reference tissue sections, all the
microscopy images obtained from a stack of sequential tissue sections were registered
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to the Hoechst image of the reference section. As the latter was also registered to the
18

F-FLT and 14C-FDG autoradiography images, all microscopy and autoradiography

images were registered together by the combination of rigid and deformable registration
techniques as shown in the flow chart presented in Figure 7, and had a resulting pixel
size of 2.5 µm.

Image Registration Error Analysis
Rigid Registration – Images Acquired From the Same Section
The minor misalignments between the microscopy images coming from the same
image were resolved by manual registration as described above. Preliminary tests
utilizing difference images have indicated that visual inspection of the overlap was a
sensitive method to detect misregistrations. Misalignments as small as one pixel size
could be detected without difficulty. Therefore, the registration error of this alignment
process was considered to be under the observable limit of one pixel (2.5 µm), thus
negligible.
The accuracy of the microscopy to autoradiography image rigid registration that
was evaluated using the marker dots created around each tumor section. Specifically,
for each image pair, the total number of marker dots visible around the tissue was
randomly split into a registration landmark set and a measurement landmark set. The
rigid transformation was obtained based on the optimal alignment of the registration set,
which always contained only four points, while the rest of the landmarks served as a
measurement point set94. To evaluate the rigid registration error, the displacements
between the weighted centers of mass of corresponding points in the measurement
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point set were recorded after registration, for all of the utilized sets of images (8 tumor
models). Multiple repetitions of the registration procedure (n=30) were performed for
each tumor model, each time using different subsets of landmarks for registration and
for measurement. Mean registration error and the standard deviation were calculated
and reported for all the measurements (N = 960).

Deformable Registration – Images Acquired From Multiple Sections
To evaluate the registration accuracy of the deformable registration for the
images acquired from adjacent tissue sections, sets of corresponding landmarks were
established for the Hoechst image pairs to be registered (measurement landmark
sets)95. To ensure objective evaluation, these landmarks had to be different from those
utilized for the registration. Therefore, a different feature extraction algorithm, SIFT
(Scale Invariant Feature Transform), was used to establish corresponding points in the
two images96. To obtain a set of measurement landmarks to be used for registration
accuracy evaluation, these initial sets of points were manually processed as to assure
proper correspondence between the landmarks, and also their uniform distribution
across the section area. For each of the eight tumor models, there were 3-5 different
pairs of Hoechst images. For each Hoechst non-reference and Hoechst reference
image pair, a minimum of 30 corresponding landmarks were defined.
To obtain the registration error distribution after deformable registration of the
Hoechst image pairs, the distances between corresponding measurement landmarks in
the target image and the registered image were recorded. The average distance
between the landmarks after deformable registration was reported as the deformable
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registration error. In order to calculate a combined registration error, it was assumed
that the observed displacement values between corresponding points after image
registration were random and normally distributed over all measurements. The total
registration error was represented by its two components: rigid registration error
(autoradiography to microscopy from the same tissue section) and deformable
registration error (for microscopy images acquired from sequential tissue sections). The
total registration error was defined as the convolution of the two error components
approximated by Gaussian distributions.

2.4 Results
The initial step in the presented co-registration procedure was the rigid
registration of DAR and IFM images obtained from the reference section. Figure 9
shows image overlays representative of the point-set rigid registration results. Following
the same procedure, the 14C-FDG autoradiography and Hoechst images were
registered to the 18F-FLT autoradiography.
The distribution of rigid registration error measurements is shown in Figure 10A.
The average registration error for the rigid registration of Hoechst microscopy image to
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F-FLT autoradiography image was Erigid,Hoechst = 30.8 µm ± 20.1 µm image registration.

The mode of the distribution was 16.1 µm, while the maximum displacement value was
129.1 µm. The distribution of displacement values for 14C-FDG to 18F-FLT
autoradiography image indicated an average registration error of Erigid,autorad =
26.4 µm ± 17.9 µm. The mode of the distribution was 9.01 µm with a maximum
displacement value of 107.4 µm.
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Figure 9. Transparent overlay in false colors of C-FDG autoradiography (red), F-FLT autoradiography (green),
Hoechst (light blue). Panels A and C show images manually registered based on the observed tissue outline. Panels
B and D present the same images after rigid point-set registration.

The distribution of deformable registration error measurements is shown in
Figure 10B. These registration errors were calculated for 3-5 different pairs of Hoechst
images for each of the eight tumor models. The success rate of the deformable
registration algorithm was uniform across the utilized tumor models (average error
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ranges from 19.73 to 25.66 µm). For each Hoechst non-reference and Hoechst
reference image pair, we had a minimum 30 defined corresponding landmarks, for a
total of 1057 measurements.

Figure 10. (A) Distribution of displacement values between corresponding landmarks after rigid point-set image
18
14
18
registration (Hoechst image registered to F-FLT autoradiogram and C-FDG autoradiogram registered to FFLT autoradiogram); (B) Distribution of displacement values between corresponding landmarks: before
deformable image registration (red dotted line), after deformable image registration (blue continuous line).

Figure 11 presents transparent overlays of images before and after the
deformable registration procedure. Specifically, the top row demonstrate the effect of
applying the calculated transformation for Hoechst images, while the bottom row reveals
the overlay of two complementary aspects of the tumor biology (hypoxia and blood
flow), before and after the deformable registration procedure.
The calculated error of the deformable registration was
Edeformable = 23.1 µm ± 17.9 µm, which is similar to that reported in three-dimensional
tissue reconstruction studies utilizing the same deformable registration algorithm95. The
distributions of the registration errors before deformable registration (red dashed line,
maximum error 308.3 µm) and after (blue line, maximum error 108.4 µm) are shown in
Figure 11B.
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The total registration error was calculated as the convolution of the two error
components: σtotal =

2
2
σ rigid
+ σ deformable
= 44.86 µm.

Figure 11. Illustration of deformable registration results using IFM images in semi-transparent overlay. Arrows
indicate an area highlighting how initial misalignment was corrected by deformable registration.
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2.5 Discussion
The aim of this study was to develop and evaluate a semi-automated approach
to multi-modality registration of autoradiography and microscopy images acquired from
sequential tissue sections. While this procedure was developed specifically for
histopathological validation of PET tracers, it can be used as a tool for any colocalization studies involving various imaging probes, especially when the images of the
probe distributions cannot be obtained from a single tissue section.
Earlier studies registering autoradiography and microscopy images utilized
manual co-registration, to the observer’s best ability. Rigid transforms (translation,
rotation, scaling) were applied to images in transparent overlay, followed by convolution
with a 200 µm Gaussian kernel to minimize the effect of any remaining misalignment
errors, and/or rebinning, where the images were resampled to 200×200 µm grid for
pixel-by-pixel analysis76, 77. Others have implemented automated rigid registration
algorithms, followed by image rebinning to 200×200 µm pixel size to account for the
estimated accuracy of image co-registration78. While these approaches are considered
acceptable, manual registration of images from different modalities even when acquired
from a single tissue section may be prone to observer bias and lack in reproducibility97.
Lower resolution of autoradiography images combined with the background noise can
obscure the edges of the tissue sections enough to hinder the manual registration
relying on aligning tumor section outlines (Figure 9A, C). Furthermore, rebinning the
data to the coarser pixel size with or without blurring can result in a significant loss of
information as tumor microenvironment can change significantly on the scale of
200 µm70, 98, 99. Image intensity-based registration was also successfully employed using
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cross-correlation, mutual information, and minimization of image dissimilarity97, 100.
Nevertheless, inter-modality image registration cannot rely on image content, as to
avoid alignment of regions that have similar content but are not co-localized.
Landmark-based registration remains the most objective registration method for multimodality imaging73.
To allow for objective three-dimensional registration of in vivo images obtained
with MRI and PET, and ex vivo histology and autoradiography images, Humm et al.
introduced the stereotactic system employing Teflon fiduciary markers driven into the
tumor73. Similar to the approach of Humm et al, the present study adopted the principle
of creating landmarks visible on all registered images, i.e. autoradiography and
microscopy images. However, invasive fiducials were not used in this study, to avoid
tumor microenvironment disruption and interference with uptake of the PET tracer101.
The most direct way to compare the intratumoral distribution of a PET tracer to
designated biological aspects on tumor section images would be to obtain all pertinent
information from a single representative tissue section. Because this is practically
unfeasible most of the time, the images of PET tracer distribution were obtained from
one tissue section, while the adjacent sections were utilized to acquire microscopy
images to complete the microenvironmental map of the tumor. The novelty of the
proposed approach is the use of Hoechst image-based registration, where the features
of two Hoechst images acquired from the adjacent tissue sections were used to
establish spatial correspondence between these two tissue sections and then obtain the
deformation needed to co-register all images acquired from these sections. As a result,
even though the images were acquired from adjacent sections, the misregistrations
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caused by inevitable deformations that occur during tissue processing were minimized.
An additional novel aspect of the co-registration methodology presented here is the
elimination of manual registration of images obtained from different tissue sections, or
from different modalities. In this study, we have demonstrated the feasibility of the
proposed registration procedure and evaluated its accuracy.
The combined registration error of microscopy images to 18F-FLT
autoradiography images was 44.86 µm. This registration error is smaller than values
previously reported between 100-200 µm in studies using the same general imaging
modalities76-78, 99. Furthermore, since the registration error is smaller than the inherent
resolution of 18F or 14C autoradiography, further studies analyzing the co-localization
between radiotracers and targeted biological pathways will be minimally influenced by
image registration.
Some aspects of our methodology need discussion. The typical size of the
marker dots placed around tissue section using mixture of fluorescent marker (Hoechst
33342) and the 14C ink was about 0.2-0.5 mm. This is similar or larger than the typical
size of the structures (microenvironment features) seen in the images. However, it is not
the marker dots but rather their weighted centers of mass that were used for registration
of autoradiography and microscopy images. Therefore, the actual size of the marker
dots was not limiting the accuracy of registration. However, while the autoradiography
images are characterized by linear response and wide dynamic range (16-bit),
fluorescent Hoechst images do not have the same dynamic ranges. Because the pointset registration is based on aligning the weighted centroids of the masked marker dots,
the mentioned difference in dynamic range may potentially induce inaccuracies in
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center of mass calculation. However, in the study presented here this issue was
mitigated by creating marker dots as close to circular features as possible. We have
conducted preliminary tests using a uniform mixture of fluorescent marker and the 14C
ink to confirm that the weighted centers of mass calculated for both autoradiography
and microscopy images coincide in the majority of cases.
In the deformable registration of distinct Hoechst images, the definition of
corresponding landmarks between two images can be inaccurate. Since the landmarks
locations are only used as soft constraints in the registration algorithm, this uncertainty
does not affect the final registration accuracy. However, during the deformable
registration error evaluation, the uncertainty in landmark localization contributes to the
final reported registration error. To minimize this effect, the final measurement point sets
defined for each Hoechst image pair were manually processed and any observed
inconsistencies eliminated by manual removal of the corresponding landmarks.
Finally, the study presented here has been conducted using small animal tumor
model specimens. However, the methodology can also be applied at the clinical stages
of PET tracer validation to confirm concordance between the pattern of PET tracer
uptake and the spatial distribution of its intended target in patient tumor specimens.
In conclusion, a comprehensive, semi-automated method for deformable coregistration of autoradiography and microscopy images acquired from sequential tissue
sections was developed and evaluated. The registration method addresses significant
non-linear deformations induced by tissue processing, and eliminates the need for
potentially subjective manual co-registration of multimodality images acquired from
adjacent sections. We demonstrated that this method is more accurate than the other
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currently available methods. The improvement in registration accuracy could further
advance correlative studies of the microenvironmental factors governing PET tracer
intratumoral distribution. Furthermore, it can aid the studies aimed at investigation of
spatial co-localization of different aspects of tumor biology that can be revealed by
combination of autoradiography and/or microscopy imaging.
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3. Analysis of spatial concordance between the intratumoral patterns
of cell proliferation and 18F-fluorothymidine uptake at
microenvironmental level
3.1 Introduction
Using ex vivo imaging of tumor tissue sections, it is possible to obtain images of
the intratumoral distribution of PET tracer and compare them to images of specific
molecular markers indicative of the targeted biological pathway. Establishing spatial
concordance between these two images provides the experimental confirmation that the
spatial pattern of the intratumoral PET tracer distribution correctly represents the spatial
pattern of the underlying targeted biological features. This analysis can be conducted
utilizing many different approaches. We present one way, specifically addressing the
issue of spatial coincidence between segmentation areas defined based on FLT
autoradiography and positive staining areas defined on proliferation microscopy images.
In the first chapter of this thesis, the details of multi-modality co-registration between
DAR and IFM images were presented. Utilizing this co-registration workflow, the
geometric misalignments between images of FLT tracer and cell proliferation marker
uptake were minimized, allowing for an accurate spatial concordance analysis.
Previous histopathological validation studies that sought to demonstrate the colocalization between intratumoral PET tracer uptake and tumor microenvironmental
markers used thin tissue autoradiography and microscopy to image the tumor
microenvironment. The resulting images were co-registered and pixel-by-pixel intensity
correlation analysis was employed to obtain global indicators of spatial co-localization
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(e.g. Pearson coefficient) between the grayscale intensities in the image-pairs76-78.
However, this type of analysis is sensitive to many factors that could significantly
influence the results. Depending on the ratio of the size of the pixels and the inherent
resolution of 18F autoradiography70, 102, 103, local spatial autocorrelation between adjacent
autoradiography pixels may occur, invalidating the Pearson correlation assumption of
independence between individual pixel values. In addition, the Pearson correlation
coefficient is highly sensitive to the presence of noise and non-specific staining/uptake
in both considered images (autoradiography and microscopy)104. Furthermore, while
phosphor plate autoradiography is characterized by linear response over a wide range
of signal intensities, the response of the immune-histochemical microscopic imaging is
generally non-linear. Therefore, the Pearson correlation coefficient, which tests the
strength of a linear functional relationship between the pixel intensities of two coregistered images, may not be the optimal way to measure the spatial co-localization of
these two signals.
Threshold-based analysis of spatial co-localization of two image sets provides an
alternative and more intuitive approach to demonstrating the spatial concordance
between the microscopic pattern of 18F-FLT tracer uptake and the pattern of cell
proliferation in images from thin tissue specimens. Since the images sets are accurately
co-registered, overlap analysis metrics such as the Dice coefficient and analysis of
receiver operating characteristic (ROC) curves can be used to directly assess the colocalization of the two signals.
By its definition, a threshold value differentiates between two mutually exclusive
target groups within a given population. Therefore, when a threshold is applied to a FLT
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uptake image, the result is a binary map containing positive pixels – representative of
an area where there should be active cell proliferation, and negative pixels – where
there should not be any proliferating tumor cells. This is a classic example of a
dichotomous classification problem, widely encountered in computer-aided diagnostic
systems105. When the classification is conducted with a priori knowledge of where the
actively proliferating tumor regions are, then a contingency table or confusion matrix can
be determined (Figure 12).

Figure 12. Example of contingency table utilized in the dichotomous classification problems presented in this study.
The gold standard is defined based on histopathological images of cell proliferation. The classification output is
based on the FLT uptake image intensity chosen as a threshold value.

The performance of the classification system, in this case FLT thresholding, can be
analyzed using measures for a specific threshold value105. For each selected FLT
uptake threshold value, the true positive fraction corresponds to the portion of correctly
classified pixels containing active cell proliferation. Correspondingly, the true negative
fraction represents the portion of the pixel “population” which was correctly classified as
44

not containing actively proliferating cells. The false positive fraction represents the
group of incorrectly classified pixels as containing active cell proliferating, and the false
negative fraction, that part of the pixels that were incorrectly classified as not containing
cell proliferation.
Since FLT thresholding is not an ideal classification tool for identifying the spatial
distribution of cell proliferation, providing representative threshold-based classification
performance metrics for single threshold values does not provide a representative
indication of the overall performance of the classification method. In many medical
applications, ROC curves are determined by plotting the true positive fraction
(sensitivity) against the true negative fraction (specificity)106, for all possible threshold
values. The calculated area under the ROC curve has been used as an estimate of how
well the investigated classification method performed, independently of the threshold
value.
The Dice coefficient has been used as a similarity measure over pairs of given
sets obtained from image segmentation69, 107, 108. It can be directly calculated based on
the threshold-based metrics defined in the contingency table. By analyzing the Dice
coefficient values over all possible threshold values, this measure can be used to detect
the optimal threshold values for which the majority of the proliferative tumor subvolumes
were detected.
The goal of this study was to investigate the spatial concordance between the
pattern of intratumoral 18F-FLT uptake and the spatial distribution of cell proliferation
markers using tumor tissue obtained from small animal xenograft tumor models. By
using Dice and ROC analysis, it can be demonstrated that high FLT uptake values are
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within areas of active cell proliferation. Furthermore, analyzing threshold specific
measures, the specificity and sensitivity of the proposed classification method can be
directly evaluated for any threshold value. As mentioned in Chapter 1, this study will
provide the first experimental data set demonstrating in vivo correspondence between
areas of high FLT high and areas of active cell proliferation. This spatial
correspondence was analyzed based on two-dimensional analysis of images obtained
from individual tumor sections from different tumor specimens. The details of this study
have been previously published in Radiotherapy and Oncology109.

3.2 Methods
Experimental design
The detailed description of the experimental procedures used in this study was
presented in the chapter 2. Briefly, head and neck tumor xenografts were developed in
immune-compromised mice. When the tumors reached approximately 1 cm in diameter,
animals were anesthetized. Before sacrifice, the animals were injected i.v. with a bolus
containing the 18F-FLT radiotracer. Two consecutive intraperitoneal injections of BrdU,
used as a marker of cell proliferation77, were administered. After sacrifice, the tumors
were excised, frozen, and embedded in OCT. From each tumor specimen, several
stacks of consecutive 8 µm thick tissue sections were obtained. Using one tumor tissue
section selected from each stack, phosphor plate autoradiography was utilized to image
the intratumoral distribution of 18F-FLT76. 14C standards were simultaneously exposed
with the tissue sections. The DAR images were digitized and image intensity values
were converted to actual activity concentration (Bq/mm2).
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Figure 13. Representative microscopy images sets for the two tumor models used in this study. Top row shows
images of blood flow and cell proliferation. Bottom row shows corresponding H&E image.

Following immuno-histochemical processing of the tissue sections, BrdU images
of cell proliferation were acquired with fluorescence microscopy (Figure 13). H&E
images were acquired.

Image processing
The DAR and IFM images were co-registered using a combination of deformable
and rigid registration as presented in the previous chapter, with an overall registration
error of less than 45 µm.
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To define the regions of interest for the spatial concordance analysis, the extent
of the viable tissue was delineated based on H&E images. First, any non-tumor tissue
(muscle, lymphatic tissue) and specimen edges were removed using Photoshop CS4
Extended tools. These corrected H&E images were processed in MATLAB, and utilizing
color segmentation and morphological processing, the viable tissue masks were
obtained as a subset of the whole tissue area (Figure 14).

Figure 14. Viable tissue (shown in white) and necrotic areas (shown in grey) obtained from H&E images. Only the
viable tissue is utilized for analysis.

To minimize the effect of residual registration misalignments, the DAR images were
rebinned to 50 µm per pixel, utilizing the mean intensity value for the resulting pixels. A
different approach was adopted for the rebinning of proliferation images. In the first
step, all non-specific staining that occurred in necrotic parts of the tissue was masked
out using the viable tissue mask. Secondly, the corrected images were binarized
utilizing a local Otsu thresholding method110, 111. The resulting mask was used to remove
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all low-intensity non-specific staining inside the viable tissue, obtaining corrected
images of cell proliferation. Since the viable tissue masks were obtained from different
(albeit adjacent) tissue sections, manual removal of any remaining high-intensity
staining artifacts was performed. In a final step, a global Otsu threshold was applied to
the corrected cell proliferation images to obtain only true positive areas of BrdU staining.
The resulting binary image was rebinned to 50 µm pixel size, so that the value assigned
to each pixel represented the fraction of its area that was positively stained. The
resulting image was referred to as the proliferative cell density image throughout the
rest of the study. To preserve consistency in the analysis of the regions of interest, the
viable tissue masks were also rebinned to 50 µm per pixel. For the purpose of image
analysis, the BrdU-based proliferative cell density images obtained as described above
were used to establish the ground truth images of cell proliferation. Specifically, a
proliferative cell density threshold value was chosen such that the truth set was
sensitive enough to include the majority of BrdU positive cells. Therefore, if the 50-by-50
µm unit area contained more than 1% stained surface it was considered a positive. The
resulting binary image was defined as the truth set (T).

Image analysis and statistical evaluation
An instance of the measurement set (M) was obtained by segmenting the FLT
DAR image. By varying the segmentation threshold from the minimum to the maximum
DAR image intensity levels, a range of measurement sets was obtained. The overlap
between the truth set, T, and the measurement sets was analyzed as a function of the
threshold value. For each FLT threshold value, the intersection sets were calculated as
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presented in Figure 12: the true positive set (
(

), the true negative set

), the false positive set (

), and the false negative set (

). Using these intersection sets, the Dice coefficient (D) was calculated for each
threshold value107, 108:
=
D (T , M )

T ∩M
TP
=
1
1
( T + M ) 2 ( TP + FN + TP + FP )
2

ROC curve analysis106 was also carried out. This classic test of diagnostic
accuracy was adapted to investigate the reciprocal relationship between the sensitivity
and specificity of FLT segmentation correctly classifying the pixels where active cell
proliferation occurred. The ROC graph depicts on the y-axis the ratio between the
number of correctly classified pixels and total number of pixels for each instance of the
measurement set, also called sensitivity (or recall):
Sensitivity (T , M ) =

TP

( TP + FN )

The x-axis indicates the ratio between incorrectly classified pixels and the total number
of pixels, also mentioned as 1-Specificity (or false positive rate):
FPR (T , M ) = 1 −

TN

( FP + TN )

To compare the relative efficacy of this classification method for different scenarios, the
area under the curve (AUC) was obtained. The AUC represents a significant singlevalue indicator of the expected performance of segmented FLT images correctly
representing the spatial distribution of BrdU positive cells. The AUC values are recoded
as values between 0 and 1, where 1 represents an ideal classification result. Areas less
than1 occur when significant false positive and false negative fractions are recorded.
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Areas of 0.5 stand for random classification result. Good classification performance is
indicated by values generally equal or greater than 0.7105.
While 18F autoradiography is characterized by high imaging spatial resolution, it
is nevertheless significantly lower than the resolution necessary to resolve microscopic
details such as those visible in the IFM images of BrdU uptake. Therefore, partial
volume effect results in lowering of the signal at an arbitrary location and spilling it over
into the adjacent regions in the image. To study the influence of image resolutioninduced effects on the spatial concordance results, the BrdU images were blurred with a
300 µm Gaussian filter as to create simulated autoradiography images. The size of the
blurring kernel was an estimate of the 18F positron autoradiography resolution when
imaging with phosphor plates, based on existing literature102, 103, 112. Subsequently, these
BrdU-based simulated autoradiography images were segmented as was done in the
case of the FLT autoradiography, and were used to obtain measurement sets in the
threshold-based image analysis as described before.
All statistical tests were done utilizing the Statistical Toolbox offered within the
MATLAB R2010a package. Since the data samples were small (8 FaDu tumors, 7
SQ20B tumors), normality of the data could not be clearly demonstrated. Therefore,
non-parametric hypothesis testing was utilized, specifically the two-sided rank sum test
(Mann-Whitney U test). A P value less than or equal to 0.05 was considered statistically
significant.
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3.3 Results
Tumor characteristics
Whereas both investigated tumor lines were human squamous head and neck
cancers, they expressed different rates and patterns of growth (Figure 13). FaDu, a
human hypopharyngeal cell line produced tumors at least twice as fast as SQ20B
(laryngeal origin) for the same caliper-measured volume. Both tumor models present
heterogeneous pattern of BrdU DNA incorporation across the tumor section, with higher
uptake generally adjacent to well vascularized areas.
ROC analysis
The ROC analysis consists of a two-dimensional representation of classifier
performance (FLT-positive pixel correctly classifying BrdU positive pixel) and is
visualized within the unit square (Figure 15). Therefore, the AUC values were between
0 and 1, with values closer to unity indicating a greater accuracy of the classification
method. For FaDu tumors, the median value for the AUC was 0.74 with a range of 0.550.84, while for SQ20B tumors the AUC median value was 0.51 with a range of 0.420.69. The difference in medians was significant at 5% level. Higher values of the AUC
provide direct evidence of the spatial concordance between the areas of increased
activity in the FLT DAR images and the areas of increased proliferative cell density.
A sensitivity analysis was also conducted where the variation of the ROC curves
and AUC values was assessed as a function of the threshold value applied to obtain the
truth set. Therefore, the measurement sets were compared against more conservative
truth sets. These sets were obtained by increasing the minimum proliferative cell density
value above which the resulting pixel in the truth set was positive (10% vs. 1%). For
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FaDu tumors, the new median AUC value was 0.73 with a range of 0.5-0.84, not
significantly different from the original value. Similarly, for SQ20B tumors, the new
median AUC value of 0.48 (0.41-0.6), was not significantly different from the value
calculated for 1% proliferative cell density. The AUC values were still significantly
different between the two tumor lines.

Figure 15. Examples of ROC curve analysis for utilizing segmented FLT images to predict the spatial distribution of
cell proliferation. Presented results were representative of the two tumor specimens presented in Fig. 2 (AUCFaDu =
0.73; AUCSQ20B = 0.52). The diagonal dashed line (AUC = 0.5) represents the random chance line.

Dice coefficient analysis
For each FLT threshold level, a Dice coefficient value was calculated (Figure 16).
The Dice coefficient values indicated the fractional amount of overlap between the
segmented FLT area and the BrdU truth set. For FaDu tumors, the median value for the
maximum Dice coefficient was 0.61 (range: 0.26-0.77), while for SQ20B it was 0.55
(range: 0.44-0.69). The difference in median values was not statistically significant at
5% level (P value = 0.31).
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Figure 16. Dice overlap analysis. Presented results were representative of the two tumor specimens presented in
Fig. 2 (DFaDu = 0.69; DSQ20B = 0.55). Arrows indicate FLT threshold level for which the maximum Dice coefficient
was calculated for the selected tumor sections.

A significant difference between the median values of the FLT thresholds at which the
maximum Dice coefficient occurred was recorded. For FaDu tumors, it was 38.5%,
while for SQ20B tumors it was 7%. As for ROC analysis, the sensitivity of overlap
analysis as a function of the proliferative cell density threshold value was assessed.
Using a more conservative truth set, the maximum overlap decreased, as indicated by a
median Dice value of 0.38 for FaDu tumors and 0.16 for SQ20B tumors. The difference
in median threshold value at which maximum overlap occurred remained statistically
significant between the two tumor lines, 57% for FaDu tumors, and 24% for SQ20B
tumors.
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Effect of autoradiography resolution
To study how finite imaging resolution-blurring present in autoradiography
images affects the results of the analyses presented above, the BrdU microscopy
images were convolved with a Gaussian kernel of the same size as the estimated
resolution of 18F autoradiography.

Figure 17. ROC and Dice analysis of blurred BrdU image vs. BrdU-derived truth set: top panel – ROC analysis
(AUCFaDu = 0.86, AUCSQ20B = 0.59), bottom panel – Dice coefficients vs. threshold levels of blurred BrdU image.
Arrows point to the threshold values at which the maximum Dice coefficient occurs (DFaDu = 0.79, DSQ20B = 0.56).

These blurred BrdU images were used to create the measurement sets, while the highresolution BrdU images were used to determine the truth set. Whereas there was
perfect spatial co-localization between the images used to produce the two sets used in
the analysis, the ROC analysis indicated less than perfect spatial concordance between
blurred BrdU and proliferative cell density images (Figure 17). FaDu models presented
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a median AUC of 0.92 (0.82-0.95), while for the SQ20B tumors the AUC was 0.7 (0.550.82). In addition, the overlap analysis indicated that the median value for the maximum
Dice coefficient was 0.77 (0.59-0.85) for FaDu tumors and 0.61 (0.49-0.72) for SQ20B
tumors.

3.4 Discussion
The spatial concordance between intratumoral FLT uptake and the distribution of
cell proliferation markers was studied using small animal tumors representative of
human squamous head and neck cancers. The results presented here complement
those of previous studies in which 18F-FLT was investigated as a tracer for PET imaging
of cell proliferation without addressing the issue of spatial correspondence between the
patterns of FLT uptake and cellular proliferation41, 46, 55, 113. While less important for many
diagnostic applications of FLT PET imaging, the issue of spatial concordance is of
utmost importance in radiation oncology treatment planning, where boundaries of the
high PET tracer uptake region are used to define shape and extent of radiation dose
distribution used for boosting the patient’s high risk GTV subvolume.

Experimental setup
Some of the experimental details need further discussion. In this study,
automated immuno-histopathological processing of the tissue and standardized image
acquisition protocols allowed consistent results in obtaining the microscopy images. The
necessary confidence in the truth set definition was further ensured by careful
examination and correction of staining artifacts. In addition, Otsu thresholding has been
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shown to be one of the most efficient algorithm for segmentation of fluorescent
images111. As for the sensitivity of the truth set to the proliferative cell density value used
to define the truth set, a preliminary analysis was conducted. ROC analysis results were
not significantly different, indicating that the specificity of FLT segmentation was
consistent in classifying the active proliferation areas indicated by more conservative
truth sets. The overlap analysis indicated the expected results for a gradual decrease in
extent of the truth set. This study was based on the observations from two tumor lines,
utilizing specimens from 15 tumors total. By expanding the study to include more tumor
specimens and other cell lines, will allow for further evaluation of FLT images as
indicators for determining the spatial distribution of cell proliferation.

FLT for imaging spatial pattern of cell proliferation in FaDu and SQ20B tumors
Thresholding the FLT autoradiography was the investigated method to retrieve
the spatial pattern of cell proliferation. As pointed out by the ROC analysis of FaDu
tumor data, the median AUC value of 0.74 indicated that FLT segmentation was a good
method for identifying proliferating subvolumes. In addition, this finding is a direct
indicator that FLT high-uptake regions in the FaDu tumors are spatially concordant with
areas of increased proliferation. Dice coefficient values varied across the range of FLT
threshold values selected for particular instances of the measurement sets. The
presence of a peak Dice value revealed that there were FLT segmentation values for
which there was a maximum amount of overlap between the thresholded FLT image
and the BrdU-defined truth set, and the true positive fraction was greater than the false
positives. For FaDu tumors, this was achieved at a median threshold value of 38.5%.
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For the SQ20B tumors, the maximum amount of overlap between FLTsegmented areas and the truth set was similar, as indicated in the median value of the
Dice coefficient (0.55). While not significantly different from FaDu data, these values
consistently occurred for very low FLT threshold values (median of 7%). This indicates
that for SQ20B tumors, FLT-segmented areas include a maximum amount of the truth
set only when the majority of the intensity values were included into the segmented set
(large false positive fraction). Since it is expected that higher intensity values be colocalized with the areas of active proliferation, this result provides direct evidence of the
lack of specificity in retrieving the spatial pattern of cell proliferation. ROC analysis also
supported this finding, where the median AUC value was 0.51. The low AUC value
(representative of random chance in ROC analysis) indicates that for this tumor type,
the areas of increased FLT uptake were not spatially concordant with the areas of
increased proliferation.

Tumor morphology
The results obtained for the SQ20B tumor model were unexpected. The
experimental methodology was identical for the both head-and-neck tumor models. The
only fundamental difference between them that could explain the observed differences
was in their pattern of growth and the resulting distribution of microenvironmental
features. The faster growing FaDu tumors, presented a highly compartmentalized
spatial pattern of cell proliferation (Figure 13). There was uniform BrdU uptake all
throughout the well-vascularized area, creating a proliferating rim surrounding hypoxic
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and necrotic tumor regions. In contrast, a slow, lobular type of growth induced a
dispersed uptake pattern of BrdU in the SQ20B models.

Imaging resolution
Since the microscopic features observed in the cell proliferation images were on
a smaller scale than the autoradiography resolution, it was necessary to investigate the
direct effect of finite imaging resolution on the spatial concordance results. This was
done with the aid of the BrdU images blurred with the kernel simulating the resolution
limitation of autoradiography images. Thresholding of the blurred BrdU image was less
specific at retrieving the spatial pattern of original BrdU staining distribution in SQ20B
tumor xenografts, than in the FaDu tumors (Figure 17). Since the same blurring kernel
was applied to both tumor models, this effect could only be caused by the degree of
heterogeneity in the spatial distribution of cell proliferation. The SQ20B tumor models
had a more dispersed distribution of proliferation markers. Correspondingly, blurring
affected these tumors more so than the FaDu tumors, which had a more
compartmentalized distribution of cell proliferation. For the latter tumor model, the
typical size of the actively proliferating ‘‘compartments’’ was similar or larger than the
resolution of autoradiography, therefore blurring did not affect their general spatial
distribution. On the other hand, for the SQ20B model, there was no clear
compartmentalization of proliferation. After blurring, the typical size of the observed
features was significantly larger than of those seen in the original BrdU microscopy
image.

59

FLT-based delineation of actively proliferating tumor subvolumes
When applying the tumor-specific median value for the FLT threshold that
produced the maximum overlap between areas of increased proliferation and
segmented FLT area, the results were indicative of the difference between the two
tumor lines. As emphasized with the blue contour line (Figure 18), the regions
delineated on SQ20B tumors coincided with the whole tissue section area in the
majority of cases, while for the FaDu tumors the actively proliferating “compartment”
was correctly delineated. To visualize the possibility of misinterpretation of segmented
FLT regions, the 50% of maximum intensity threshold value was utilized for images from
both tumor lines (red contour, Figure 18), as a global threshold that is commonly utilized
for FLT PET segmentation35, 114. There were distinct areas delineated on both tumors.
This threshold value resulted in segmented areas that were more conservative, but
which were still spatially concordant with areas of increased cell proliferation in FaDu
tumors. At the same time, the segmented areas significantly underestimated the extent
of the cell proliferation in the SQ20B tumors.

Spatial concordance of FLT uptake and cell proliferation
As illustrated by the xenograft tumor data presented above, tissue morphology
and the resulting spatial heterogeneity of cell proliferation, together with finite imaging
resolution, significantly affect the feasibility of using 18F-FLT DAR images to specifically
predict the spatial distribution of cell proliferation, as imaged with BrdU. This directly
affected the study conclusions about the generality of FLT spatial concordance with cell
proliferation. While for FaDu tumors spatial concordance was clearly supported by the
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data acquired, the same cannot be said about SQ20B tumors. However, this does not
imply that there is no spatial concordance between FLT uptake and cell proliferation in
both of the tumor models at a cellular level. The experiment with the blurred BrdU image
confirmed that the spatial concordance analysis for SQ20B tumors is inconclusive due
to the mentioned combined effect of imaging resolution and spatial proliferation pattern
heterogeneity. The dispersed pattern of cell proliferation imaged in these tumor samples
could not be resolved by autoradiography with 18F. As a result, the overall high tracer
uptake across the tumor section correctly indicated the ubiquitous presence of active
cell proliferation throughout the tissue section specimen. Nevertheless, the noise
associated with 18F autoradiography and the overlap of the “spill-off” regions
corresponding to each cell containing the tracer, made it such the high-activity regions
recorded in the autoradiographic image did not coincide with the location or the extent
of the imaged spatial pattern of cell proliferation. Depending on the tumor-tobackground uptake ratio while imaging in vivo, FLT PET may correctly determine that
for tumors such as SQ20B, the whole tumor is actively proliferating. Nevertheless, this
aspect needs further analysis.

Conclusion
In this study, autoradiography images were utilized for the delineation of distinct
tumor subvolumes of increased cell proliferation. The results indicate the difficulties in
this process present even when utilizing autoradiography imaging, which is
characterized by the resolution superior to that of any small-animal PET or clinical PET
scanners. In PET imaging, the averaging effect induced by positron travel alone can
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significantly reduce the ability of FLT uptake images to correctly reproduce any map of
cell proliferation. It seems that as long as the compartmentalization of the tumor
microenvironment presents features that can be resolved with the employed imaging
modality, subvolume delineation is feasible.

18

Figure 18. Tumor subvolumes delineated based on thresholding F-FLT autoradiography. FLT threshold contour
(iso-intensity) lines were then superimposed on BrdU microscopy images.

These observations agree to other studies investigating the ability of 18F-FDG69
or 18F-FAZA70 to reproduce the intratumoural distribution of their intended biological
target. Further studies of the spatial concordance between the actual intratumoural
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pattern of FLT uptake in PET images and the spatial distribution of cell proliferation in
human pathological samples could elucidate the situations in which imaging with this
particular tracer could provide useful information on the spatial distribution of actively
proliferating cells.
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4. PET simulation
4.1 Introduction
In chapters 2 and 3, the first specific aim was addressed. Specifically, the spatial
concordance between FLT uptake pattern and the spatial distribution of cell proliferation
was analyzed at a microenvironmental level. The microscopic uptake of FLT was
imaged with DAR, while the pattern of BrdU uptake represented a surrogate for the
spatial distribution of active cell proliferation. It was observed that when tumors present
a pattern of cell proliferation that is highly dispersed throughout the tumor, even highresolution imaging modalities such as DAR could produce incorrect predictions about
the extent and spatial distribution of proliferative tumor subvolumes. While spatial
coincidence between high FLT uptake regions and actively proliferative subvolumes
was demonstrated in tumors with highly compartmentalized/aggregated features of cell
proliferation, there were no conclusive results across the utilized tumor lines. This
emphasized the need for histopathological validation of FLT PET imaging for imageguidance applications in radiotherapy.
In most diagnostic applications of PET imaging in oncology, PET data is used to
extract metrics such as SUVaverage, SUVMAX, or SUVpeak that allow to test for the
presence of disease or to predict characteristics of the tumor as a whole. Validation of
such PET imaging application can be done by establishing the correlation between
single-value SUV-based metrics characterizing in vivo PET tracer uptake and ex vivo
pathological indices representative of the target biology (e.g. proliferation index) over a
population of patients46.
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However, when PET imaging is used for radiation therapy guidance, e.g. to
identify aggressive tumor subvolumes that can be targeted with selective dose
escalation, it is the spatial characteristics of the PET images that are used to define the
treatment dose distribution. Correspondingly, validation of PET imaging for radiation
treatment planning requires an approach that allows testing the spatial coincidence of
the region of high tracer uptake, as imaged with PET, and the biological/morphological
features of interest. The gold standard for validating PET imaging for radiotherapy
image guidance is histopathological validation, whereby non-invasive PET images are
registered to ex vivo histopathological images enabling the analysis of their spatial
association. Unfortunately, the required registration of PET and histopathological data is
a subjective process that is prone to error. Furthermore, the registration is not always
feasible due to the significant deformation of the specimen after the surgical excision.
Several groups have reported experimental methods for high-precision co-registration of
histopathological images with in vivo PET images from small-animal models achieving a
registration error of less than 0.3 mm. However, these methods either necessitate
invasive fiducials that can alter the tracer uptake73, or require embedding the animal in
liquid molds72, 115, which can potentially interfere with normal animal physiology and
prohibit their adaptation to human validation studies.
Various surrogate histopathological validation techniques involving human
specimens have been developed to test the accuracy of PET-based gross tumor
volume delineation. In these studies, in vivo PET images are segmented utilizing
selected thresholding protocols and either segmentation volumes or their largest
diameter is compared to those of surgically resected tumor specimens116-118. While good
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correspondences were reported between PET-derived metrics and those obtained from
ex-vivo imaging, the methodology used in these studies does not provide the spatial
information necessary for the analysis of the spatial correspondence between the PET
tracer distribution in tissue and corresponding biology119, 120.
In this study, an alternative method for histopathological validation of PET
imaging for radiotherapy image-guidance applications is presented. This method
circumvents the problems associated with the registration of in vivo PET images with
microscopic histopathological images. The approach is demonstrated using smallanimal tumor models. However, the method is equally applicable to the clinical PET
imaging validation using whole-tumor specimens of human origin.
Utilizing whole tissue specimen sections, autoradiography was used to obtain
images of the microscopic distribution of the PET tracer. Tumor microenvironment and
morphology images were obtained from the same locations. Using the reconstructed
tracer 3D distribution, realistic synthetic PET (sPET) images were obtained. MonteCarlo models of clinical and research PET scanners exist in literature121-124 and they can
be used to perform accurate simulations of all physical processes contributing to PET
image formation and to arrive to sPET images that are representative of a given 3D
microscopic tracer distribution. However, as a proof of principle, a simplified approach to
PET image simulation was utilized in this study, where sPET images were obtained by
convolution of the intratumoral tracer distribution with a 3D kernel representative of the
spatial resolution of a small-animal PET scanner.
By virtue of their generation, sPET images are perfectly registered to the
underlying autoradiography data that in turn can be precisely registered to the
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histopathological images of tumor microenvironment79. Therefore, the resulting sPET
image sets can be used to study the spatial concordance between the pattern of the
tracer uptake as depicted in PET images and underlying microenvironment, without the
confounding effects of registration uncertainties.

4.2 Methods
Tumor Models and Radiotracer
As before, human head and neck tumor xenografts (SQ20B) were developed in
male athymic mice (NCr-nu/nu; National Cancer Institute), from bilateral flank
subcutaneous inoculation of 106 cells/site. Animals were maintained according to the
protocol approved by the Institutional Animal Care and Use Committee at Virginia
Commonwealth University. The PET simulation and tracer validation process was
demonstrated using a different tracer from FLT, as to demonstrate its versatility. 14Clabeled 2’-Deoxy-2’-[F]fluoroglucose (American Radiolabeled Chemicals, Inc.) was
utilized as the investigated tracer. This compound is chemically identical to the clinically
utilized 18F-FDG, and it was utilized for the autoradiography resolution advantage that
the 14C β- low-energy decay particle offers.

Tumor Tissue Collection
After the tumors reached 1 cm in diameter as measured by caliper, the animals
were anesthetized with a mixture of oxygen and isoflurane. At 80 min before planned
animal euthanasia, a bolus injection containing Hoechst (0.4 mg/20-g mouse), and 925
kBq of 14C-FDG was administered by tail-vein injection. After animal sacrifice, tumors
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were immediately excised. The entire surface of the exposed tissue was coated with
Davidson Marking System black ink (Bradley Products, Inc.), and then embedded in
OCT.
For embedding, a special jig was built (Figure 19A), which was similar to a
previously reported prototype. Specifically, parallel holes were drilled in two rigid plastic
boards (6 mm thickness). Their spacing and diameter was chosen such that they would
fit 18G needles (BD Biosciences) in such a way as to allow a tumor specimen to fit in
between the needles. The needles were first inserted into the bottom plastic plate, then
through a disposable plastic mold used for specimen freezing. The excised tumor was
positioned in the mold containing the OCT, between the needles. Then, the top plate
was placed on top of the mold, allowing the needles to go through. After the assembly
was tightened with screws, it was placed on dry ice for freezing. After the OCT
solidified, the needles were retracted and the tumor specimens were sectioned with a
Leica CM1850 UV cryostat (Leica Microsystems) at 8-µm tissue section thickness and
mounted on glass microscope slides.
During cutting, a stack of 3-4 consecutive tissue sections was collected every
120 µm throughout the specimen. In addition, for every sequential stack of tissue
sections, a digital image of the cutting plane was acquired utilizing a Pentax Optio S7
digital camera in macro mode employing a remote trigger. The camera was mounted on
a custom-built plastic frame that fitted the cryostat work-window (Figure 19B). The
double ball-in-socket adjustable locking mount (Ram Mounts Cat# RAM-B-202AU,
RAM-B-201U, RAM-B-202U, National Products, Inc.) allowed for an accurate alignment
of the camera optical axis with the axis of the specimen holder, perpendicular to the
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cutting plane. Once camera position was selected, the joints were locked in place,
ensuring the reproducibility of the position from which the digital image of the tissue
block was taken (Figure 19C).

Figure 19. A. Freezing jig for tissue specimen. B. Cryostat setup with mounted camera on double-jointed adaptor.
C. Example of the tissue specimen digital photo with hollow columns as registration fiducials. The margins of the
tissue were inked to increase the contrast of the tissue boundary.

Tissue Imaging
One section from each image stack obtained at every sampling location was
used for autoradiography. The sections covered with a thin plastic wrap (<20 µm) were
placed in contact with the phosphor plates in light-tight cassettes for 5 days at room
temperature. The imaging plate was read with Typhoon 9410 Variable Mode Imager
(GE Healthcare) to obtain images of the FDG distribution (Figure 20B). The reader
output was digitized in grayscale TIFF images with 25 µm pixel size. The grayscale
intensities were converted to activity concentration based on the images of 14C
standards that were co-exposed with the tissue sections to the same imaging plates.
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Figure 20. Tumor B images. A. Microscopy image of hematoxylin and eosin staining. Image was acquired at 20x
using a motorized research Olympus BX61 microscope. B. Autoradiography image. C. Simulated PET image
slice. Both B and C images were normalized to the maximum activity value in the whole tumor. All images are at
the same scale.

Since the tissue utilized for autoradiography becomes dehydrated and can be
damaged during plastic film removal, adjacent tissues were utilized to image the desired
aspects of tumor morphology and/or microenvironment. For this study, H&E staining
was performed on the tissue section adjacent to the section used for autoradiography.
Any other relevant stain (e.g. hypoxia, proliferation, apoptosis, vasculature, etc.) can be
carried out as well. The H&E microscopy image was deformably registered to the
autoradiography image from the same stack using the methods described in chapter 2.
The H&E images were utilized to define the extent of the tumor tissue (whole tissue
mask) and the subset corresponding to the viable tumor tissue (viable tissue mask)
(Figure 20A). This was done via MATLAB R2010a script utilizing the Image Processing
and Statistical Toolboxes. The script was an adaptation of a color-based segmentation
algorithm using K-means clustering, presented on the MathWorks site
(http://www.mathworks.com/products/image/demos.html). The results of the viable
tissue segmentation were reviewed by a pathologist to confirm validity.
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3D reconstruction
In order to reconstruct the 3D spatial distribution of the intratumoral FDG uptake
along with the 3D distribution of the viable tissue, a two-step process was utilized. First,
the digital photo images of the cutting plane containing the inked tissue specimen
(Figure 19C) were rigidly registered using the visible hollow needle tracks. The
photographic images were then re-binned as to match the pixel size of the
autoradiography images. In the second step, the pairs of already registered
autoradiography and the viable tissue images from each sampling location were coregistered to their corresponding aligned digital photos. Since non-linear deformations
occur during tissue cutting and mounting, it was necessary to use deformable
registration for this step. Both autoradiography and H&E images are very different from
the digital photos of the tissue. Therefore, intensity-driven or internal landmark-based
registration strategies were not feasible. A contour-based deformable registration was
utilized instead. The contours, represented by point-sets corresponding to the tissue
boundaries (which remained intact during tissue section transfer onto the glass slide),
were extracted from both digital photo and H&E microscopy image. A deformable
transformation was obtained by aligning the contours, which was then applied to the
autoradiography and viable tissue mask. Both registration steps were implemented in
MATLAB R2010a using the rigid and non-rigid applications of the coherent point drift
algorithm88.
At the end of the registration process, all images were stacked into threedimensional matrices, and rebinned at 50×50×120 µm per voxel utilizing the mean
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values, in order to eliminate any residual misalignments after image registration. The
resulting autoradiography stacked volume was analyzed for three-dimensional
consistency. Consistency was defined in terms of smoothness the signal between
consecutive slices101. Specifically a normalized correlation coefficient was calculated
between each pair of consecutive slices, and the mean and standard deviation of the
correlation coefficients was reported as a measure of the 3D consistency of the
reconstructed volumes.
The error of the rigid registration of the digital photo images was measured in a
separate experiment. Instead of a tumor specimen, a suture filament was tensioned in
the tumor mold and embedded as presented above. The block was sectioned and the
digital photo images were obtained and registered as before. The 3D coordinates of the
suture filament in each section were detected. Utilizing linear regression, a line was
fitted through the points such that the perpendicular distances from the data to the fitting
model were minimized. The mean and standard deviation of the residual projection
distances between fit model and data points were reported as the registration error.

PET simulation
The simulated PET image was obtained by convolving 3D autoradiographic data
sets with the 3D point-spread-function kernel of the Siemens Inveon small-animal PET
scanner (Siemens Medical Solutions, Inc.) using MATLAB R2010a (Figure 20C). The
line-spread-function was measured utilizing a custom-built water-equivalent phantom
containing a line source. The line source was a mouse tail-vein catheter (Braintree
Scientific, Inc.), with an inner diameter of 0.17 mm, filled with 26.6 MBq/ml of 18F
72

solution. The PET scan setup was replicated according to NEMA recommendations for
spatial resolution measurement125. The point-spread-function in each dimension was
derived from the Gaussian fits of the line profile126. The results obtained in-house were
consistent with previously published data127, 128.

Spatial concordance analysis
For this study, FDG was chosen as an example of a PET tracer under validation.
The spatial coincidence between the areas of high FDG uptake in the sPET images and
the spatial distribution of the viable tissue, as defined based on H&E segmentation
(Figure 20A), was analyzed utilizing overlap analysis (10). For each activity value found
inside the volume defined by the whole tumor mask, the sPET image was thresholded
obtaining a distinct segmentation 3D volume. These 3D tumor subvolumes were
compared to the H&E-based viable tissue delineation (ground truth), and different
intersection sets were obtained: true positive, true negative, false positive and true
negative sets108. Based on these, Dice coefficient values were calculated to determine
the spatial overlap between segmented volumes from sPET images and the viable
tumor tissue at each threshold value. Receiver-operating-characteristic (ROC) curves
were utilized to evaluate the overall performance of FDG segmentation at classifying
pixels as viable or non-viable. The area under the curve was used as a measure of how
well FDG thresholding determines the spatial extent of the tumor viable tissue. As the
purpose of this study was to introduce a novel methodology for PET imaging validation
for image-guidance in radiotherapy, the ability of FDG sPET to identify viable tumor
tissue was used as an illustration only.
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4.3 Results
Comprehensive sampling of the tumor tissue throughout the specimen is
essential to the presented methodology. For the two SQ20B tumors (denoted A and B)
that were utilized in this experiment, the total number of 4-section stacks were 41 and
48. The recorded time stamps on the digital photos indicated that for an experienced
user, one 4-section stack could be consistently obtained every two minutes (120 µm
inter-stack distance).

Figure 21. Orthoslices through tumor B. All images are normalized to the maximum tumor activity registered in
the aligned autoradiography stack. Color bar indicates [0, 1] range.

3D reconstruction and PET simulation
The registration error of the rigid registration step in the reconstruction procedure was
6.56 ± 4.78 µm. Figure 21 depicts orthogonal slices though the reconstructed 3D FDG
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autoradiography image-set, confirming the three-dimensional coherence of the set. This
was also confirmed by an analytic measure of 3D consistency of the analyzed sets. The
mean and standard deviation of the normalized intensity correlation between pairs of
successive slices in the restacked autoradiography volume presented high correlation
values 0.84 ± 0.05 (range: 0.73-0.91) and 0.94 ± 0.02 (0.86-0.97).
The sPET images were obtained by direct convolution of the reconstructed 3D
autoradiography data was with a 3D Gaussian kernel representative of the point spread
function of the Siemens Inveon small-animal PET scanner, as measured at the center of
the scanner’s field of view: 1.56 mm tangential FWHM, 1.62 mm radial FWHM, and 2.12
mm axial FWHM. Figure 20C presents a slice through the resulting sPET image set at
the location corresponding to the autoradiography image presented in Figure 20B. As
can be seen from the image, application of the 3D blurring kernel changes the image of
the tracer uptake dramatically. The Dice overlap between the volumes obtained by
thresholding of both sPET data set and the actual activity map reconstructed from
autoradiography (the threshold set at 70% of maximum activity in both cases) was 0.0
and 0.1 as measured using Dice coefficients for tumor A and tumor B, respectively.
These values increased to 0.02 and 0.34 for the threshold set at 50% of the maximum
activity; 0.28 and 0.47 at 30% threshold, and 0.87 and 0.79 for 10% threshold. The
difference between sPET and 3D autoradiography is illustrated in Figure 22, which
shows 3D rendering of the thresholded volumes.
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Figure 22. Rendered tissue outline with segmentation volumes. A. 3D reconstructed autoradiography. B. sPET.
Threshold values represent percent of maximum intensity.

Spatial concordance between the FDG uptake pattern and viable tissue distribution

Figure 22B depicts the distinct tumor segmentation subvolumes resulting from
sPET image thresholding performed using different activity values. To evaluate the
classification performance of the thresholding operation performed on FDG sPET
images as a method of viable tissue delineation, the area under the ROC curve (AUC)
was computed as a single metric indicative of the performance of the investigated
classification method. The results show that FDG segmentation is a good classifier for
voxels containing viable tissue: AUCA = 0.74 and AUCB = 0.81, confirming that regions
of higher FDG uptake are spatially co-localized with regions of viable tissue within the
tumor.
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Figure 23. Three sequential sections through tumor B, presenting viable tumor tissue (white) as a subset of the
whole observable tissue (gray). The colored lines present iso-intensity lines from the sPET image sequence.
Thresholds are percent of maximum intensity. All images are at the same scale.

The maximum overlap between the FDG segmented volumes and the viable
tissue subvolume as indicated by Dice coefficient values, was 0.8 for tumor A (at 22% of
max intensity) and 0.88 for tumor B (at 14% of max intensity). FDG segmentation was
highly sensitive at determining the extent of the viable tissue at these thresholds (true
positive fraction, tumor A: 0.94, tumor B: 0.99), but it was not specific (true negative
fraction, tumor A: 0.17, tumor B: 0.36). Figure 23 presents a sequence of viable tissue
masks from tumor B, with overlaid iso-intensity lines obtained from the corresponding
sPET image set. The segmentation volumes from which the iso-intensity lines were
extracted covered the viable tissue for tumor A and tumor B respectively: 5.8% and
3.4% at 70% of maximum intensity, 39.6% and 27.9% at 50%, 84.2% and 81.4% at
30%, and 99.8 and 100% at 10% of maximum intensity.

4.4 Discussion
Our novel method of histopathological PET imaging validation does not require
registration of in vivo PET data with histopathological images, a step prone to error and
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subjectivity. Instead, the whole tumor specimen is used to obtain both histopathological
data and the intratumoral distribution of the tracer that is subsequently used to generate
a synthetic PET image. In this manner, all confounding factors associated with the
registration of PET images to histopathological images are bypassed. Therefore, the
only registration errors with potential effects on the spatial concordance analysis are the
residual misalignments encountered between autoradiography and microscopy images
obtained at each tumor sampling location (less than 45 µm).
Currently, a number of PET tracers targeting different aspects of tumor biology
are being developed38, and new PET-based dose escalation clinical trials 20, 22 have
been proposed and conducted.

3D reconstruction
The tissue processing workflow is highly adaptable and inexpensive to implement
for a wide range of microtomes, for frozen specimens. Different jigs can be built for
different tumor sizes using readily available materials. Similarly, the camera mount can
be adapted to multiple microtome geometries, and any compact digital camera with
remote trigger can be utilized. While there are institutions with highly specialized
infrastructure for 3D tissue reconstruction94, the method presented in this study meets
the demands of the validation goal: to obtain a 3D intratumoral distribution of a PET
tracer that can be used to generate sPET images precisely registered to
histopathological data. The 3D morphology of FDG uptake demonstrated good spatial
correlation between neighboring slices, even though a non-negligible inter-slice distance
was utilized
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Histology studies have demonstrated that tumor vascular tree is the main factor
affecting the shape and location of spatial gradients of the tumor microenvironment
functional aspects such as hypoxia or cell proliferation65, 82-84, 98. Consequently, tumor
microenvironmental architecture is characterized by a typical spatial scale between
50 µm and 250 µm. Therefore, the chosen distance of 120 µm between sampling
locations ensured that all major spatial features of different aspects of the tumor
microenvironment were properly sampled, allowing for a coherent representation of 3D
spatial distributions of tracer activity (Figure 21) and viable tissue, as well as any other
tumor microenvironmental parameter (e.g. hypoxia, cell proliferation, etc.).

PET simulation
The most accurate approach for creating sPET images would be a Monte Carlo
simulation of the PET image formation starting with a 3D autoradiography microscopic
tracer uptake map as a heterogeneous source and using readily available models for
clinical and research PET scanners. These models allow comprehensive simulations of
the physical performance of a particular PET scanner model and generate the raw data
that can be used to reconstruct realistic PET image corresponding to any given
heterogeneous source of activity. To illustrate the validation methodology, a simplified
approach was used in this study. The 3D map of the intratumoral activity distribution, as
imaged with autoradiography, was convolved with a 3D Gaussian kernel representative
of the point spread function measured in the center of the field of view of the Siemens
Inveon small-animal PET scanner. The FWHM size of the adopted convolution kernel
was considered appropriate since the reconstructed tumors were generally small (≤1 cm
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in largest diameter) and the size of the point spread function was shown to be constant
between the center of the field of view and approximately 15 mm radial offset127, 128 for
the scanner in question. For larger tumors tumor specimens, convolution with a spatially
variable Gaussian kernel would have to be implemented.
The sPET images are based on 3D stacks of autoradiography data. Therefore,
the accuracy of autoradiography in describing the microscopic uptake of the tracer is
very important. In this study, 14C-labeled FDG was used to maximize the resolution and
to simplify the experimental procedures. The effective resolution for thin tissue
autoradiography with this β- emitter was reported at 100 µm FWHM129. When utilizing
higher energy positron emitters (e.g. 18F), the resolution of the microscopic tracer
uptake map may degrade. However, the estimated resolution for 18F autoradiography
(~200-300 µm) would induce an uncertainty in the actual source position that is less
than the uncertainty induced by positron travel in PET imaging with a clinical scanner
(~1.76 mm)68.
The obvious effect of convolving/blurring autoradiography activity maps is the
dramatic change in spatial heterogeneity of the tracer uptake (Figure 22). As indicated
by the overlap analysis between sPET and 3D autoradiography there is little to no
overlap between segmented volumes for higher activity values. This result is similar to
previous studies illustrating the averaging effects of PET imaging with FDG69. Clinical
PET imaging resolution (18F and a 80 cm bore scanner) is about 4-5 mm currently and
theoretically limited at about 2 mm FWHM because of positron travel and annihilation
photon non-colinearity{{}}. The inherent blurring effect introduced only by these physical
properties of PET image acquisition will have a profound effect on the spatial
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concordance between tracer uptake on PET images and the actual microscopic
intratumoral uptake, emphasizing the need for experimental validation of PET imaging
for the purpose of radiotherapy image guidance.

Spatial concordance analysis between FDG uptake and viable tissue
Based on the illustration involving the analysis of the co-localization between
FDG high uptake regions and the spatial distribution of viable tissue, it was
demonstrated that distinct subvolumes indicative of the location of viable tissue can be
accurately delineated (Figure 23). For example, if the FDG PET image would be
segmented with a 30% of maximum uptake threshold, more than 80% of the viable
tissue would be included in the delineated subvolumes. By extending this type of
analysis over a population of patients, the delineation uncertainty associated with
clinical segmentation protocols can be directly quantified. This would give a clear
indication of the efficacy with which biologically targeted radiotherapy can be
implemented.
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5. Analysis of spatial concordance between the intratumoral patterns
of cell proliferation and 18F-fluorothymidine uptake in simulated PET
images
5.1 Introduction
The use of PET imaging for biologically guided radiotherapy has been proposed
before8. There are different approaches to PET image-guided radiotherapy37, 38. The
clinical feasibility of 18F-FDG PET-based dose escalation has already been
demonstrated in clinical trials20, 22. Similarly, 18F-FLT PET image data can be potentially
utilized to design biologically-adaptive treatments, where subvolumes characterized by
active cancer proliferation are targeted with higher doses35-38.
As reported in previous chapters, there is no current published data
demonstrating that the intratumoral pattern of FLT uptake as imaged with PET is
representative of the underlying spatial distribution of active cell proliferation.
Furthermore, it has been shown that partial volume effect associated with PET imaging
can potentially degrade the spatial correspondence between in vivo PET images and
the distribution of the targeted biological pathway69, 70. In chapter 3, it was demonstrated
that subvolumes delineated on high-resolution DAR images may not accurately localize
the areas of active cell proliferation109. To understand the potential of 18F-FLT PET for
guiding radiation therapy and improving the clinical outcomes of patients treated with
FLT-based dose escalation, it is necessary to investigate the spatial correspondence
between the FLT PET signal and cell proliferation spatial distributions.
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In chapter 4 a novel PET imaging histopathological validation method for imageguidance applications was introduced. This method was designed such that it
circumvents the difficulties associated with registering in vivo PET images with ex vivo
histopathological images. Using the proposed validation methodology, it was
demonstrated that while the tracer uptake as seen in sPET image was not as spatially
heterogeneous as the actual microscopic uptake map, it still provided valuable spatial
information about the topography of the targeted tumor biological aspect. In this
chapter, a similar analysis was conducted between a synthetic PET image of FLT
uptake and the distribution of cell proliferation markers from a whole small-animal tumor
specimen.

5.2 Methods
Tumor model and radiotracer
Human head and neck tumor xenografts (FaDu, SQ20B) were developed in male
athymic mice as before. This study presents the analysis for a single SQ20B tumor. The
size of the tumor as measured by caliper was 9.2 mm by 7.3 mm by 6.9 mm.
14

C-labeled 3’-deoxy-3’-F-fluorothymidine was the investigated tracer. It was

synthesized by Moravek Biochemicals, Inc. (Brea, CA), utilizing an established protocol,
utilizing 5´-benzoyl-2,3´-anhydrothymidine as a precursor80, 81. The specific activity of the
compound is 55.7 mCi/ml, and the radiochemical purity is 99.1% as tested with high
performance liquid chromatography. The 2’-position on the thymidine ring was labeled
with the 14C isotope. The 14C-labelled FLT compound is chemically identical to the
previously used 18F-FLT, hence it will be referred to as FLT for the rest of the study
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(Figure 24). As in chapter 4, the long-lived isotope was utilized for the autoradiography
resolution advantage that the 14C low-energy decay β- particle offers.

18

Figure 24. Structural similarity between utilized tracers. Left: tracer tagged with F FLT, with the positron emitter
14
on the ribose ring at position 3’. Right: tracer tagged with C at position 2’ on the thymine ring. A stable fluorine
atom was placed at 3’ position to maintain the biochemical properties of the tracer.

Experimental procedure
The experimental procedures were replicated as presented in chapter 4. The
single difference was that the bolus injection contained Hoechst (0.4 mg/20-g mouse),
and at most 1.11 MBq of 14C-FLT. The tissue was embedded utilizing the special
freezing jig described in the previous chapter. Tissue histochemical processing and
imaging was conducted as presented before79. From each sampling location, stacks of
four sequential tissue sections (8 µm) were obtained. All sections were imaged for
Hoechst staining, images utilized for image registration79. One image was used for DAR
imaging, while the adjacent sections were utilized to obtain tissue morphology
information (H&E staining) and the distribution of active cell proliferation (BrdU uptake)
(Figure 25). There were 56 stacks of 4-sections each obtained from the studied tumor.
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Figure 25. Images obtained from sampling location 45 out of 56. H&E for tissue morphology. Hoechst for blood
14
flow and diffusion. DAR image of C FLT distribution. BrdU uptake as a surrogate for active cell proliferation. All
images are on the same scale.

As presented before, H&E images were utilized to delineate the extent of the viable
tissue as a subset of the entire tissue section109. Since there is no a priori information
about the location and distribution of viable tissue versus necrosis during in vivo PET
imaging, the region of interest for testing spatial concordance in this project was the
entire tumor specimen, a union of both viable and non-viable tissue (Figure 26).

Figure 26. Section 30 out of 56. Left, H&E and superimposed contours for delineated viable tissue (blue) and
the outline of the entire tissue section (black). Right, corresponding regions of interest for viable and non-viable
tumor tissue. Images are on the same scale.

Based on the available BrdU images, proliferative cell density images were obtained as
described in chapter 3. Specifically, the areas of BrdU positive staining were extracted
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from the image as a binary mask. The proliferative cell density images were obtained by
rebinning these masks to 50 µm per pixel, where the fraction of the Brdu positively
stained area in each rebinned pixel was assigned as the new pixel value. To obtain a
binary mask of the extent and spatial distribution of cell proliferation, a proliferative cell
density threshold value was selected such that the resulting set included the majority of
actively proliferative tumor regions. The maximum proliferative cell density in the studied
tumor specimen was 40% as defined by the stained area per 50 µm pixel. The threshold
that was most sensitive to the extent of cell proliferation as imaged with BrdU was 1%.
To present the variation of the results in the presence of more conservative truth sets,
5% and 10% thresholds on proliferative cell density were included in the study (Figure
27).

Figure 27. Obtaining truth sets. Left panel: section 30 proliferative cell density grayscale image. Right panel: truth
sets based on the proliferative cell density image thresholded at different levels.
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3D reconstruction and PET simulation
The three-dimensional reconstruction of the intratumoral FLT uptake was
conducted as presented in the previous chapter. Specifically, all registered images from
each stack obtained at each sampling location were co-registered to their corresponding
digital photos of the tissue in the OCT block (Figure 19).

Figure 28. Orthoslices sets. All images were normalized to maximum activity and present values between [0, 1].
All images are at the same scale.

The consistency of the three-dimensional activity pattern of the reconstructed
autoradiography stack was evaluated by measuring the normalized intensity correlation
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between neighboring slices throughout the tumor volume (mean ± standard deviation =
0.93 ± 0.04). The sPET images were obtained by convolving the 3D stacked
autoradiography with a 3D Gaussian kernel representative of the Siemens Inveon smallanimal PET scanner spatial resolution (Figure 28). The spatial correspondence between
sPET activity map and the original microscopic FLT uptake was evaluated.

Spatial concordance analysis
Threshold-based and threshold-independent metrics of spatial concordance
between FLT uptake pattern as seen on the sPET image and the Brdu-defined
proliferation truth sets were adapted from the 2D analysis presented in chapter 3 to
three-dimensional analysis. To conduct a spatial concordance analysis based on
continuous classifiers such as the FLT 3D DAR and sPET images, a binary gold
standard needs to be established, which will define the classification truth for each
observation in terms of two mutually exclusive classes: actively proliferating tumor
versus non-proliferating tumor.

Figure 29. Image set at section 30 level. Left panel: Brdu-based truth set (1% proliferative cell density threshold).
Middle panel: autoradiography. Right panel: synthetic PET image. The autoradiography and sPET images were
normalized to the maximum value in the 3D volume. All images are on the same scale.
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As mentioned before, the gold standard for the extent and spatial distribution of cell
proliferation are the BrdU-defined truth sets (Figure 29). Both DAR and sPET images of
FLT uptake were thresholded to obtain instances of measurement sets (observations).
Varying threshold values were applied to these image sets and the resulting
segmentation measurement sets were directly compared to the gold standard. For each
observation, i.e. for each threshold level applied to either the 3D DAR or sPET image, a
contingency table was created as in chapter 3 (Figure 12). By varying the threshold
values over all the available activity levels in the FLT uptake images, the sensitivity and
specificity of the classification method could be determined as a function of threshold
level 109. The ROC curves were plotted and the area under the curve was measured as
presented before. Furthermore, for each instance of the measurement sets, the Dice
coefficients were also calculated based on the contingency table metrics. Both ROC
curve analysis and Dice coefficient curves were plotted for truth sets obtained for 1%,
5%, and 10% proliferation cell density.
Based on the Dice curves a threshold level was established for which the Dice
coefficient reached a maximum value, indicating maximum amount of spatial
information retrieved by the FLT-based segmentation volume about the truth set shape
and extent. For this particular threshold value, the following metrics were computed
based on the corresponding contingency table (Figure 12): sensitivity, specificity,
accuracy. All these metrics will be discussed in the following sections in terms of the
studied classification problem: FLT thresholding classifying actively proliferating or nonproliferative pixels within the volume of interest.
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5.3 Results
Correspondence between FLT uptake in 3D autoradiography data and sPET
image set
As illustrated by the orthoslices in Figure 28, the convolution process significantly
affects the spatial heterogeneity of the FLT uptake. In order to investigate the
correspondence between the pattern of FLT uptake as recorded in the 3D
autoradiography and sPET, the image sets were normalized to maximum activity and
thresholded at different thresholds across the [0, 1] range (Figure 30).

Figure 30. Plot of Dice coefficient values as a function of threshold values applied to normalized FLT uptake (DAR
and sPET) images. The red line emphasizes the overlap between DAR and sPET segmentation volumes for 30% of
max activity threshold. This threshold produces a sPET segmentation volume that best represents the spatial extent
of cell proliferation.

Since the sPET image is inherently registered to the autoradiography set from which it
was created, the discrepancies between sPET images and the underlying microscopic
uptake of FLT were directly attributed to the finite resolution of PET imaging. While
distinct tumor subvolumes can be delineated in both image sets (Figure 31), the
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mentioned difference becomes important when regions of high tracer uptake of the
tumor are considered for targeting. It is at these conservative threshold values where
the overlap between the segmented volumes on FLT and DAR coincide the least
(Figure 30), as indicated by Dice coefficient values: 0.037 at 70% of maximum activity,
0.33 at 50%, 0.6 at 30%, and 0.83 at 10%.

Figure 31. Rendered tissue outline with segmentation volumes. A. 3D reconstructed autoradiography. B. sPET.
Threshold values represent percent of maximum intensity. Images are at the same scale.

Spatial concordance analysis between FLT uptake and cell proliferation
The observable loss in spatial heterogeneity of the FLT uptake pattern imaged
with sPET vs. the 3D autoradiography was consistent with the ROC analysis results.
Since the 3D DAR imaging resolution is higher, smaller details of the spatial distribution
of cell proliferation could be resolved. Therefore, when thresholding FLT 3D DAR
images to retrieve the spatial extent of active cell proliferation, the AUC values were
higher than when sPET thresholding was utilized (Figure 32). This result was consistent
over all the utilized truth sets. The high AUC values in both cases are a direct
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confirmation that higher uptake values coincide spatially with actively proliferating tumor
subvolumes, for both DAR and sPET image sets.

Figure 32. ROC analysis of FLT uptake image segmentation as a classifier of the extent and spatial distribution of cell
proliferation. Different truth sets were used as gold standard for classification results: 1%, 5%, and 10% proliferative
cell density. Red dotted line is indicative of random chance. An AUC value closing unity is indicative of perfect
sensitivity and specificity of the investigated classification method given a defined truth set.

Figure 33. Dice overlap analysis between segmented volumes on FLT uptake images and the BrdU-defined truth set, as
a function of utilized FLT threshold value. Different arrows indicate the threshold value for which a maximum Dice
coefficient value occurred. Different truth sets were used as gold standard for classification results: 1%, 5%, and 10%
proliferative cell density.
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The spatial concordance between tumor regions with high FLT uptake and
actively proliferative subvolumes was also evident from the Dice analysis. While
creating increasingly conservative truth sets, the FLT uptake threshold at which the
maximum spatial information about the underlying cell proliferation pattern was retrieved
was also increasingly higher (Figure 33), for both DAR and sPET image sets. The
values of the maximum Dice coefficients for the 1%, 5%, and 10% were: 0.72, 0.52, and
0.24 for 3D DAR, and 0.6, 0.38, and 0.15 for sPET respectively.

FLT based delineation of actively proliferating subvolumes
As indicated in Figure 33, thresholding the sPET image at 30% of maximum
intensity creates a segmentation volume that was most accurate in describing the
underlying spatial distribution of cell proliferation for the BrdU-based truth set. The
resulting subvolume covered 74% of the truth set obtained with 1% proliferative cell
density threshold, presenting good sensitivity to the extent of active cell proliferation.

Figure 34. Sequential sections through tumor specimen, presenting BrdU-based truth set obtained with 1%
proliferative cell density threshold. The colored lines present activity iso-lines from the sPET image sequence.
Thresholds are percent of maximum activity. All images are at the same scale.

The overall specificity with which the delineated subvolume identified positive pixels in
the truth set was 0.62, indicating average ability to identify the negative pixels in the
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truth set. This aspect was also emphasized by a classification accuracy of 0.66 for the
utilized truth set. Figure 34 presents the 1% truth set at different locations throughout
the tumor volume. The illustrated overlap between the 30% threshold iso-line and the
truth set provides for a visual confirmation of the sensitivity and specificity of the
method.

5.4 Discussion
Non-invasive imaging of active cell proliferation has been proposed for
radiotherapy guidance. Taking advantage of the biochemical properties of FLT and the
long half-life of 18F, PET imaging with this tracer has been receiving a lot of attention for
treatment adaptation in biologically guided radiotherapy37. Nevertheless, the potential
impact of PET imaging resolution limitations may compromise the accuracy of
delineating tumor subvolumes that are to be targeted with increased doses. Each image
voxel may contain independent regions of active cell proliferation, and an unaccounted
combination of necrotic tissue, viable non-proliferating and viable actively proliferating
subvolumes (Figure 4).
In this study, the spatial concordance between FLT uptake pattern as imaged
with PET and microenvironmental distribution of active cell proliferation was assessed.
Synthetic PET images were obtained from the reconstructed microscopic pattern of FLT
uptake (Figure 28) as described in chapter 4. The extent and spatial distribution of
active cell proliferation were defined based on the uptake of BrdU, an acknowledged
exogenous marker of cell proliferation (Figure 27) as described in chapter 3. The two
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data sets were accurately co-registered using techniques previously described in this
work.
The spatial concordance analysis was conducted on imaging data obtained from
tumor xenografts developed in immuno-compromised mice. Since animal tumor models
are characterized by growth dynamics, morphology and vascularization different from
those encountered in human tumors, the FLT uptake images utilized throughout this
validation study are not likely to be representative of the FLT uptake images from
human patients. However, this study is not aimed at making inferences about the
differences between FLT uptake in animal and human tumors. The animal tumors
utilized in this study were characterized by highly heterogeneous microenvironments
consisting of a wide range of physiological states. Correspondingly, the FLT uptake
pattern of observed in DAR imaging as well as that of BrdU nuclear incorporation
observed in IFM imaging from these tumors were spatially heterogeneous (Figure 25).
Hence, they were valid experimental platforms for assessing spatial concordance
between the two imaging sets. Furthermore, they were perfect tools to develop and
optimize PET tracer validation methodologies that may be readily translated to human
specimens.
Another important consideration is that there are physiological differences
between animal and human tumors that directly affect the absolute levels of FLT
intratumoral uptake. The levels of endogenous thymidine are significantly higher in
rodents51-53. Correspondingly, FLT competes with the serum thymidine for all stages in
the cellular incorporation mechanisms. Therefore, it is expected that the FLT uptake is
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less than the levels encountered in human tumors. However, these factors do not affect
the investigation of spatial characteristics of intratumoral uptake of FLT.
Furthermore, FLT is metabolized in human tumors via glucoronidation (liver
metabolism) within 60 minutes post tracer injection. This does not occur in rodents
which may influence the absolute uptake levels of FLT in rodents. However, this study
aims at analyzing the spatial pattern of FLT entrapment in the studied tumors and its
correspondence to the spatial pattern of cell proliferation. Related to the FLT
metabolism problem, another potential contention with the presented validation
methodology would be that the sPET images are representative of static PET imaging.
While it has been shown that kinetic analysis of dynamic FLT PET data is needed in
some cases to accurately quantify FLT uptake53, 130, good agreement has been
demonstrated between dynamic PET uptake data and the standard uptake value
obtained 45-60 minutes after injection using static PET acquisition55, 131. Furthermore,
FLT standard uptake value has been shown to be stable between 55 and 100 minutes
post injection132. These studies suggest that static FLT PET imaging can provide
accurate uptake data in a less logistically demanding approach compared to dynamic
scanning. Therefore, the synthetic PET images developed from the intratumoral FLT
microscopic uptake after 80 minutes of uptake are representative of actual static PET
images corresponding to the investigated tumor specimen.
For the single tumor specimen utilized in this study, the microscopic FLT uptake
pattern as imaged with 3D DAR is spatially concordant with actively proliferative tumor
subvolumes. Furthermore, the macroscopic pattern of FLT uptake imaged with sPET,
while significantly different than the 3D DAR pattern, it still provides spatial information
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about the underlying spatial distribution of cell proliferation. By expanding the analysis
over a larger set of tumor specimens, the delineation uncertainty associated with
different segmentation protocols could be quantified and optimal cell-line specific
threshold values could be determined to delineate subvolume characterized by active
cell proliferation.
Dice coefficient curve analysis presented a distinct feature, consistent over all the
utilized truth sets, for both DAR and sPET image sets. The presence of a peak in the
Dice coefficient variation over the given thresholds values, a value that was distinct from
the all-inclusive minimum threshold, indicated the existence of a specific sPET/DAR
threshold value that maximized the number of correctly classified voxels (Figure 33).
When introducing more conservative BrdU-defined truth sets (5%, 10%), the Dice peak
moved towards higher threshold levels, confirming that areas that contained higher FLT
uptake values, also contained more actively proliferating cells. This result is a direct
confirmation of the spatial concordance between the pattern of FLT uptake and the
spatial distribution of cell proliferation for the specimen used in this illustrative example.
The flatter Dice curves recorded for sPET images are a result of the lower resolution of
the imaging modality. The large features in the sPET FLT uptake pattern could not
accurately resolve all proliferation spatial features (Figure 28). The fraction of incorrectly
classified pixels was always greater in the case of the sPET image set due to the
mismatch in imaging resolution, affecting the slope of the Dice curve before and after
the maximum value. This effect was also evident when more conservative truth sets
were utilized within the same imaging modality. Since the same set of segmentation
volumes were utilized to determine increasingly more conservative truth sets, a larger
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fraction of incorrectly classified pixels were included in the delineated subvolumes,
creating a flatter Dice curve and lower values for the maximum.
The high AUC values obtained for the single investigated tumor specimen,
suggest that segmenting images of FLT uptake is an accurate method of distinguishing
between proliferating and non-proliferating voxels, as defined by the BrdU truth sets. In
Figure 32, the ROC curves and corresponding AUC values were presented. While not
as high as when the 3D DAR FLT uptake image set was utilized for determination of the
extent and spatial distribution of cell proliferation, the sPET AUC values were still
indicative of a good classification method105. As in the Dice analysis, the averaging
effect of PET imaging decreased the specificity with which the spatial pattern of active
cell proliferation was retrieved, increasing the false positive pixel rate of detection, and
decreasing the overall AUC value.
The threshold-based analysis for 30% of maximum activity sPET threshold
indicated good sensitivity, average specificity, and a resulting mediocre accuracy of FLT
sPET segmentation in retrieving the spatial extent and spatial distribution of the given
truth. Figure 34 illustrates those aspects, as the 30% iso-line includes some of the truth
set at all times, while it does not manage to resolve the disseminated non-proliferating
regions. If the tumor subvolume delineated based on the 30% iso-line would be used in
biologically adaptive radiotherapy (Figure 2), it would contain the majority of the defined
actively proliferating area (74%), while encompassing only 50% of the total delineated
tumor volume. Depending on the shape of the resulting subvolume, an escalated dose
could be accurately delivered to this subvolume while limiting the surrounding normal
tissue exposure133. In conclusion, while the tracer uptake as seen in FLT sPET image

98

was not as spatially heterogeneous as the actual microscopic uptake map, it still
provided valuable spatial information about the topography of the targeted biological
feature.
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6. Conclusions
The dissertation research presented herein was focused on histopathological
validation of FLT PET imaging for biologically-guided radiotherapy. Two specific aims
were set to reach the thesis goal. First, the spatial concordance between the FLT
uptake pattern and the spatial distribution of cell proliferation was analyzed at a
microscopic level. The results of the study presented in chapter 3 provided the first set
of experimental data validating that in vivo FLT microscopic uptake coincide with areas
of active cell proliferation as imaged with conventional immuno-fluorescence methods.
In addition, this study emphasized the need for histopathological validation of FLT PET
for image-guidance applications since it demonstrated that even high-resolution imaging
modalities such as DAR could not consistently and accurately retrieve the extent and
spatial distribution of proliferative tumor subvolumes when cell proliferation is highly
dispersed throughout the tumor.
The second specific aim of the thesis addressed the development and
implementation of new histopathological validation tools to analyze spatial concordance
between volumes segmented on FLT simulated PET images and the three dimensional
spatial distribution of cell proliferation markers. Since there were no standardized
methods applicable towards the goals of this thesis, a novel approach of
histopathological validation of PET imaging for image-guidance in radiotherapy was
developed and tested in chapter 4. By relying on autoradiography-based simulated PET
images generated in such a way as to correctly represent 3D tracer distributions, the
validation workflow was reversed, circumventing problems associated with registration
of non-invasive in vivo PET images and ex vivo histopathological images. Furthermore,
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this methodology was developed with the end-goal of direct translation to validation
studies utilizing human tumor specimens, and for any combination of PET tracer vs.
targeted tumor biology. Chapter 2 presented a novel multimodality image co-registration
workflow that minimized the geometrical misalignments between autoradiography and
microscopy images acquired from sequential tissue sections. By utilizing deformable
image registration and histopathological images of blood flow as inter-section spatial
correspondences, the images acquired from up to four different sequential tissue
sections could be presented as if obtained from the same location. The improvement in
registration accuracy could further advance correlative studies of the
microenvironmental factors governing PET tracer intratumoral distribution as well as the
studies aimed at investigation of spatial co-localization of different aspects of tumor
biology that can be revealed by combination of autoradiography and/or microscopy
imaging.
The research work described here as a whole, was aimed at filling a major gap in
data supporting the use of FLT PET for the purpose of imaging the spatial pattern of
cancer cell proliferation. While much work remains to be done, the advancements
introduced by this thesis will hopefully press forward the research in this aspect of
biologically adaptive radiotherapy and open new and improved opportunities for cancer
patient care.
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